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ABSTRACT
Objectives There is a lack of evidence to inform the 
delivery and follow- up of bariatric surgery for people 
with severe obesity. The SurgiCal Obesity Treatment 
Study (SCOTS) is a national longitudinal cohort of 
people undergoing bariatric surgery. Here, we describe 
characteristics of the recruited SCOTS cohort, and the 
relationship between health and socioeconomic status 
with body mass index (BMI) and age.
Participants/Methods 445 participants scheduled for 
bariatric surgery at any of 14 centres in Scotland, UK, were 
recruited between 2013 and 2016 for this longitudinal 
cohort study (1 withdrawal); 249 completed health- 
related preoperative patient- reported outcome measures. 
Regression models were used to estimate the effect of a 
10- unit increase in age or BMI, adjusting for sex, smoking 
and socioeconomic status.
Results Mean age was 46 years and median BMI was 47 
kg/m2. For each 10 kg/m2 higher BMI, there was a change 
of −5.2 (95% CI −6.9 to –3.5; p<0.0001) in Rand 12- item 
Short Form Survey Physical Component Summary (SF-12 
PCS), −0.1 (95% CI −0.2 to –0.1; p<0.0001) in EuroQoL 
5- level EQ- 5D version index score and 14.2 (95% CI 10.7 
to 17.7; p<0.0001) in Impact of Weight on Quality of Life- 
Lite Physical Function Score. We observed a 3.1 times 
higher use of specialist aids and equipment at home 
(OR: 3.1, 95% CI 1.9 to 5.0; p<0.0001). Broadly, similar 
results were seen for each 10- year higher age, including 
a change of −2.1 (95% CI −3.7 to –0.5; p<0.01) in SF-12 
PCS.
Conclusions A higher BMI combined with older age is 
associated with poor physical functioning and quality of 
life in people seeking bariatric surgery treatment. Policy- 
makers must consider the health and care needs of these 
individuals and invest to provide increased access to 
effective weight management.
Trial registration number ISRCTN47072588.
INTRODUCTION
Obesity (body mass index (BMI) ≥30 kg/m2) 
and, in particular, severe obesity (BMI ≥40 kg/
m2) are associated with a variety of negative 
health outcomes, including increased risk of 
most major chronic diseases.1 In recent years, 
severe obesity has emerged as a major public 
health concern with rates increasing rapidly 
in a number of countries across the world, 
including the USA where the prevalence of 
BMI >40 kg/m2 rose by 70% between 2000 
and 2010,2 and around 7.7% of adults are 
now considered to have severe obesity.3 Simi-
larly, levels of severe obesity have risen in the 
UK with 2.9% of all adults in England4 and 
4% of all adults in Scotland now estimated to 
have a BMI ≥40 kg/m2.5
As the prevalence of severe obesity rises, 
effective treatment is a priority. The efficacy 
STRENGTHS AND LIMITATIONS OF THIS STUDY
 ► A limitation is that selection for bariatric surgery 
is often based on the presence of comorbidity; so 
these results, while applicable to a treatment- 
seeking population, may not be directly applicable 
to the population with severe obesity in general.
 ► The fact that almost every bariatric surgery patient 
in Scotland was recruited is a major strength of this 
study and renders it more representative than many 
studies undertaken in the field.
 ► A further strength is that the majority of question-
naires used were externally validated and wide 
ranging, containing a number of unique questions 
covering medical, social, psychological and physical 
domains.
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of bariatric surgery for significant long- term weight 
loss is well established.6 7 However, for the UK National 
Health Service (NHS), like many other health systems, 
the commissioning of bariatric surgery is low priority. 
Indeed, despite obesity prevalence being among the 
highest in the European Union, the UK performs only 9 
bariatric surgery procedures per 100 000 people,8 9 while 
Sweden, a country with a similar health service but lower 
obesity prevalence, performs 70–80 procedures per 100 
000 people.10 In North America, the rate of surgery is 
around 40–50 per 100 000 people, with the majority of 
these operations performed in the USA.8
The low prioritisation of bariatric surgery within the 
UK and the strict criteria for access to surgery, including 
complex pre- surgical pathways and pre- surgical weight- 
loss requirements,5 results in low numbers of individ-
uals with severe obesity actually receiving surgery. Those 
receiving surgery generally do so after many years of 
alternative conservative interventions, at a point when 
their mean BMI is extremely high, at around 45 kg/m2, 
and they are at a median age of 47 years.11 To date, it is 
unclear how this delay in treatment impacts on health, 
physical functioning and quality of life.
The SurgiCal Obesity Treatment Study (SCOTS) is the 
first national epidemiological study established to inves-
tigate long- term outcomes following bariatric surgery. 
This cohort study collected clinical and patient- reported 
health outcomes from treatment- seeking individuals from 
across Scotland with severe obesity before they under-
went bariatric surgery.12 The aim of the present study is to 
describe the health- related characteristics of the recruited 
SCOTS cohort and to examine relationships between 
age, preoperative BMI and other health- related factors in 
our recruited sample of adults with severe obesity from 
across Scotland.
PARTICIPANTS AND METHODS
This study was registered prospectively at the Interna-
tional Standard Randomised Controlled Trials Number 
registry. In reporting our findings, we have adhered to the 
STrengthening the Reporting of OBservational studies in 
Epidemiology Statement13 (online supplemental table 1).
Patient involvement
Patients identified via bariatric surgery peer support 
groups in Scotland were involved in the design and 
conduct of this research. During the protocol develop-
ment stage, patients provided input with regard to data 
collection and defining research questions. In addition, 
methods of recruitment were informed by discussions 
with patients during two focus group sessions. Patients 
were subsequently involved in reviewing paperwork for 
recruitment and appeared in the recruitment video. 
There is also a patient member of the independent study 
steering committee and patients were invited to a meeting 
to discuss plans for dissemination of study results.
Study design
SCOTS is a national, prospective, observational cohort 
study of adults aged over 16 years who were eligible for 
primary bariatric surgery in Scotland. Participants were 
recruited over a 4- year period from December 2013 
to February 2017. Recruitment to the cohort has now 
closed, although follow- up will continue until October 
2020. A detailed protocol for the SCOTS was published 
previously12 and is included as online supplemental 
file 1, but was amended in 2016 to reflect a smaller 
cohort size and shorter follow- up. This was in response 
to changes in national service commissioning contrib-
uting to lower numbers of bariatric surgery which, 
in turn, affected recruitment potential and planned 
sample size. Any changes from the original protocol are 
outlined below.
Participant and centre eligibility
As outlined in the protocol12 (online supplemental file 1), 
patients scheduled to undergo a primary bariatric surgery 
procedure at any of the 10 NHS- funded or 4 private 
hospitals in Scotland providing this surgery were eligible 
for invitation to the study. Inclusion criteria were that 
patients were aged 16 years or over, and undergoing their 
first bariatric surgery procedure. Patients were required 
to have capacity to consent, provide written informed 
consent and be resident in Scotland. Patients who did not 
meet these criteria or who did not have English language 
skills to complete written questionnaires were ineligible12 
(online supplemental file 1).
Recruitment procedures and consent
Patients were approached about the study at least 4 weeks 
prior to their primary bariatric surgical procedure by the 
clinical bariatric surgery team or by a research nurse in 
preoperative assessment clinics. Written signed consent 
for access to medical records, linkage of electronic health 
records and for postal questionnaires was obtained on a 
subsequent clinical visit.
Data collection
Recruited participants were asked to complete question-
naires preoperatively and at 2 years and 3 years, postopera-
tively. Prior to receiving questionnaires, participants were 
made aware (via patient information leaflets) that the 
estimated time for completion of each questionnaire was 
1 hour. The approximate time it would take to complete 
the questionnaire (1 hour) was also stated clearly on the 
first page of each questionnaire received by participants. 
Completion could be either by post or electronically via 
a secure link sent by email. Two reminders were sent by 
the participant’s chosen method and a third reminder, if 
required, was sent by post to all participants. No further 
strategy was used after three reminders.
Baseline preoperative questionnaires collected health- 
related information, including weight, medical history, 
smoking status, alcohol use, gastrointestinal symptoms, 
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urological health, depression, anxiety, health- related 
quality of life (HRQoL) and obesity- specific quality of life 
(O- QoL), life optimism, physical activity, healthcare utili-
sation, employment and social security. Comorbidity was 
assessed by self- report using a questionnaire designed 
specifically for this study (online supplemental file 2). 
Gastrointestinal symptoms were evaluated using a question-
naire developed for the REFLUX trial.14 Urological health 
was assessed using the International Prostate Symptom 
Score (IPSS)15 and the International Consultation on 
Incontinence Questionnaire- Urinary Incontinence Short 
Form (ICIQ- UI SF) wherein a score ≥6 indicates moderate 
incontinence.16 Female reproductive health data were 
obtained using a modified version of the questionnaire 
developed for the Longitudinal Assessment of Bariatric 
Surgery-2 study.17 Information on male erectile dysfunc-
tion was obtained using a modified version of the question-
naire developed for the Massachusetts Male Ageing Study.18 
Anxiety and depression were assessed using the 7- item 
Generalised Anxiety Disorder Assessment (GAD-7)19 and 
Patient Health Questionnaire-9 (PHQ-9)20 instruments, 
respectively. A PHQ-9 score ≥10 is indicative of moderate 
to severe depression, while a GAD-7 score ≥6 is reflective of 
moderate to severe anxiety.19 20 Smoking status was ascer-
tained using a questionnaire specifically developed for this 
study (online supplemental file 2). Alcohol use was deter-
mined using a modified version of the Alcohol Use Disor-
ders Identification Test.21 HRQoL was assessed using the 
Rand 12- item Short Form Survey (SF-12)22 and EuroQoL 
5- level EQ- 5D version (EQ- 5D- 5L)23 24 instruments while 
O- QoL was assessed using the Impact of Weight on Quality 
of Life- Lite (IWQOL- Lite) questionnaire.25 Standardised 
scoring was used when interpreting IWQOL- Lite question-
naires.26 Life optimism was determined using a modified 
version of the Life Orientation Test, wherein a score range 
of 0–13 reflects low optimism (high pessimism).27 Data 
on physical activity were obtained using the International 
Physical Activity Questionnaire (IPAQ) Short Form.28 
Information on participants’ employment, social security 
status and healthcare utilisation was obtained using ques-
tionnaires specifically developed for this study (online 
supplemental file 2).
Each participant’s quintile of the Scottish Index of 
Multiple Deprivation (SIMD), an area- based measure of 
socioeconomic status,29 was derived from their postcode. 
Combining a number of indicators of socioeconomic 
status across seven domains, the SIMD provides a relative 
measure of deprivation which can be used to compare 
data zones by ranking them from most to least deprived. 
The seven domains include income, employment, health, 
education, skills and training, housing, geographic access 
and crime.29
Height and weight data were collected by clinical staff 
at recruitment allowing BMI to be calculated.
We herein report baseline data recorded during the 
recruitment visit for the whole recruited cohort before 
bariatric surgery, and patient- reported outcomes for the 
subset completing baseline questionnaires.
Statistical analyses
Continuous data are reported as means and SD or 
medians and lower (Q1) and upper (Q3) quartiles 
depending on data distribution, and counts and percent-
ages are reported for categorical data. Age and BMI data 
were categorised a priori; BMI (kg/m2) is reported as 
5- unit bands (<40, 40–44, 45–49, 50–54 and ≥55) and age 
was categorised using 10- year age bands (<35 years, 35–44 
years, 45–49 years, 50–54 years and ≥55 years). Other 
baseline demographics are summarised by group.
Linear regression models were used to examine contin-
uous quality of life measures and logistic regression for 
the binary ‘need for specialist aids’ and ‘equipment in 
the home to assist with daily living’. Models were used to 
estimate the effect of a 10- unit increase in age or BMI in 
(1) an unadjusted model and (2) in a model adjusted for 
sex, SIMD, smoking status and BMI or age, respectively, 
as these factors may be associated with obesity and related 
comorbidity. Regression model effect estimates, or ORs, 
and corresponding 95% CIs and associated p values are 
provided. Data were analysed as available, without any 
imputation for missing data. All analyses were performed 
using SAS (V.9.3).
RESULTS
Over the 3- year recruitment period, a total of 548 
patients were approached and screened for eligibility to 
participate. Of these, 103/548 (19%) were excluded or 
declined to participate (figure 1). We recruited 445/548 
(81%) participants, but one participant withdrew consent 
leaving a recruited sample of 444 (81%). Of the recruited 
sample, 413/444 (93%) consented to data linkage and 
questionnaire follow- up, while 31/444 (7%) consented 
to data linkage only. Of these 413 participants, a total 
of 164/413 (40%) were not included in the subsequent 
analysis: 129 did not return a baseline questionnaire and 
35 had bariatric surgery before their baseline patient- 
reported outcome measures (PROMs) questionnaires 
were completed. Of the 129 participants who did not 
return baseline questionnaires, 84/129 (65%) progressed 
to surgery, 43/129 (33%) did not progress to surgery 
and the status of 2/129 (2%) was unknown. Completed 
preoperative baseline PROMs data for 249/413 partici-
pants (60% of those consented) were available for anal-
ysis (figure 1).
Characteristics of recruited and analysed sample
Demographic data are summarised in table 1. Participant 
characteristics were similar between the total recruited 
sample (n=444) and the analysed subset (n=249) with 
completed PROMS before bariatric surgery (table 1). 
Mean age was 46 years (SD: 9.1 years) with a higher 
proportion of women than men (71% vs 29%). Half 
of recruited participants were aged 35–49 years, with 
one- third being over 50 years. The median BMI was 47 
kg/m2 (Q1: 43; Q3: 54) with more than 21% having a 
BMI of ≥55 kg/m2. Over half of the participants (55%) 
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lived in areas of high socioeconomic deprivation (SIMD 
quintiles 1 and 2). There were no statistically significant 
differences between the analysed subset (n=249) and the 
non- analysed subset (n=195, data not shown).
Comorbidities
For the analysed sample (n=249), self- reported medical 
comorbidities, and physical, mental and functional 
measures are presented in table 2. Over 40% reported 
having at least one of hypertension, type 2 diabetes 
(T2D), back problems, anxiety/depression and gastro- 
oesophageal reflux. Over 60% of the sample reported 
more than three comorbidities. Over 40% of male partic-
ipants reported erectile dysfunction, while one- third of 
males described urinary incontinence. Half of female 
participants reported urinary incontinence. Mean depres-
sion scores reflected mild depression, although 44% of 
participants had scores indicating moderate to severe 
depression. Anxiety scores for all participants were indic-
ative of mild anxiety (median: 5.0), with half of partic-
ipants having scores indicative of moderate to severe 
anxiety. The mean life optimism score for participants 
was reflective of low optimism (high pessimism). Very 
few participants smoked (5%) and, on average, alcohol 
consumption was moderate.
Health and obesity-related quality of life
Mean SF-12 Physical Component Summary (PCS) 
and Mental Component Summary (MCS) scores were 
low—PCS: 37.0 (11.4) and MCS: 45.5 (10.3). The median 
EQ- 5D- 5L score of sample participants was 0.6 (0.3; 0.8), 
while the mean EQ- 5D- 5L Visual Analogue Scale was 55.3 
(22.1). Participants had a mean IWQOL- Lite Physical 
Function score of 56.9 (25.4) and a mean total score of 
58.5 (21.7) (table 2), where an increase in IWQOL- Lite 
score indicates a worsening in quality of life.
Physical activity
Over 80% of SCOTS participants reported undertaking 
at least 10 min of either walking, moderate or vigorous 
activity in the last 7 days and the median IPAQ score for 
the sample was 720.0 metabolic equivalent of task (MET) 
min/week. Almost one- third (29%) of participants 
reported using aids or specialist equipment to assist with 
their daily activities in the home (table 2).
Comorbidity by BMI and age
Comorbidity data are presented by BMI group and age 
group in online supplemental tables 2 and 3, respectively. 
In order to further investigate the associations between 
BMI and age on physical, mental and functional measures, 
and healthcare utilisation within the SCOTS population, 
regression analyses were performed (table 3). There was 
no significant correlation between BMI and age (correla-
tion: 0.0075, p=0.9061). Higher BMI values and higher 
ages were negatively associated with physical, but not 
mental, HRQoL scores (table 3). For each 10 kg/m2 
higher BMI, there was a change of −5.2 (95% CI −6.9 to 
–3.5; p<0.0001) in SF-12 PCS, −0.1 (95% CI −0.2 to –0.1; 
p<0.0001) in EQ- 5D- 5L score and 14.2 (95% CI 10.7 to 
17.7; p<0.0001) in IWQOL- Lite Physical Function score 
(where an increase in score indicates a worsening). We 
observed a 3.1 times higher use of specialist aids and 
equipment in the home (OR: 3.1, 95% CI 1.9 to 5.0; 
p<0.0001), adjusting for age, sex, smoking and socioeco-
nomic deprivation. For each 10- year higher age, there was 
a change of −2.1 (95% CI −3.7 to –0.5; p<0.01) in SF-12 
PCS score, −0.1 (95% CI −0.1 to 0.0; p<0.01) in EQ- 5D- 5L 
score and 5.01 (95% CI 1.8 to 8.3; p<0.01) in IWQOL- Lite 
Physical Function score, and a 3.1 (OR 3.1, 95% CI 1.9 to 
5.0; p<0.0001) times higher use of specialist aids or equip-
ment in the home, adjusting for BMI, sex, smoking and 
socioeconomic status.
Interactions were explored between smoking and 
both age and BMI (with smoking as a two- level variable 
(smoked or never smoked) due to small numbers in 
the current smoker group) and a borderline significant 
interaction between age and smoking status was observed 
(online supplemental table 4). Further exploration in the 
subpopulations of smokers (current or former) and those 
who had never smoked revealed a significant effect of age 
on the use of specialist aids or equipment in the home in 
both subpopulations, but the OR suggests a trend toward 
a slightly larger odds in those participants who had 
never smoked (online supplemental table 4). No signif-
icant effect of age or BMI on moderate to severe depres-
sion (PHQ-9) was observed in either the unadjusted or 
Figure 1 Screening, consent and follow- up. 548 patients 
were screened for inclusion in the SCOTS. Of these 548 
patients, 103 were non- eligible (62 patients had undergone 
previous bariatric surgery and 1 patient lacked the necessary 
English language skills) and 40 were eligible but did not 
consent. 31 patients consented to only part 1 of the study 
(data linkage), while 413 consented to both part 1 and part 2 
(completion of baseline PROMs). 249 baseline PROMs were 
available for analysis. PROMs, patient- reported outcome 
measures; SCOTS, SurgiCal Obesity Treatment Study.
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Table 1 Baseline sociodemographic characteristics of recruited (N=444) and analysed (N=249) samples of SCOTS 
participants
Characteristic
Recruited sample Analysed sample*
N=444 N=249
Sex, N (%) Male 123 (27.7) 72 (28.9)
Female 321 (72.3) 177 (71.1)
Missing 0 0
Age (years) Mean (SD) 46.2 (9.1) 45.9 (9.1)
Missing 0 0
Age group, N (%) <35 years 61 (13.7) 36 (14.5)
35–44 years 116 (26.1) 63 (25.3)
45–49 years 109 (24.5) 63 (25.3)
50–54 years 79 (17.8) 43 (17.3)
55+ years 79 (17.8) 44 (17.7)
Missing 0 0
BMI (kg/m2) Median (Q1; Q3) 47.2 (42.7; 53.6) 47.6 (42.8; 53.8)
Missing 1 0
BMI group, N (%) <40 52 (11.7) 24 (9.6)
40–44 115 (26.0) 64 (25.7)
45–49 116 (26.2) 64 (25.7)
50–54 71 (16.0) 44 (17.7)
55+ 89 (20.1) 53 (21.3)
Missing 1 0
SIMD quintile, N (%) 1 (most deprived) 135 (30.5) 70 (28.3)
2 108 (24.4) 65 (26.3)
3 84 (19.0) 51 (20.6)
4 68 (15.4) 34 (13.8)
5 (least deprived) 47 (10.6) 27 (10.9)
Missing 2 2
Marital status, N (%) Married/civil partnership/co- habiting Not collected 155 (63)
Single/separated/divorced/widowed 91 (37)
Missing 3
Ethnic group, N (%) White Not collected 243 (97.6)
Mixed 4 (1.6)
Asian/Asian Scottish/Asian British 1 (0.4)
African Caribbean/Black 1 (0.4)
Other 0 (0.0)
Missing 0
Education, N (%) School only Not collected 58 (23.5)
Formal qualifications through training at work 54 (21.9)
Qualification (other than a degree from college 
or university)
64 (25.9)
Degree from college or university 71 (28.7)
Missing 2
Continued
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adjusted models. However, on extending that model to 
include the interactions between smoking and each of 
age and BMI, we observe a significant interaction between 
BMI and smoking status. Considering the subpopulations 
of smokers and those who had never smoked, there was 
no significant effect of BMI on smokers, but there was 
a significant effect of BMI in those who never smoked, 
with increasing BMI having increased odds of moderate 
to severe depression (online supplemental table 4).
With regard to medical comorbidities, as listed in online 
supplemental table 5, higher BMI had a significant asso-
ciation with higher prevalence of asthma in the SCOTS 
population, while older age was associated with higher 
prevalence of hypertension, arthritis and sleep apnoea 
(online supplemental table 5).
DISCUSSION
Despite escalating levels of severe obesity in Western 
society and the concomitant increase in bariatric surgical 
procedures being performed in some countries,30 there 
is a dearth of information on the health status of people 
living with severe obesity. This is the first report from the 
national Scottish cohort study of people seeking surgical 
treatment for severe obesity. We recruited 444 adults from 
14 centres across Scotland over a 3- year period, including 
all NHS centres and major private hospitals undertaking 
bariatric surgery. We found that a higher BMI and older 
age were associated with decreased physical quality of 
life, increased use of specialist aids and equipment in the 
home and a high prevalence of comorbidities.
There has been a significant increase in the prevalence 
of a BMI ≥40 kg/m2 in recent decades; in Scotland, obesity 
prevalence has trebled in women aged 16–64 years since 
1995. However, it is hard to assess the global increase due 
to lack of reporting of a BMI ≥40 kg/m2 in national health 
survey data.31 While it is known that healthcare resource 
use increases in people with a BMI ≥30 kg/m2, with service 
use estimated to be over 25% higher than for those with a 
BMI in the normal weight range,32 few data exist for those 
with a BMI ≥40 kg/m2. In 2016, the Global BMI Mortality 
Collaboration33 conducted an individual- participant- data 
meta- analysis of 239 prospective studies and found a 2.8 
times increased risk of all cause mortality for people with 
a BMI of 40–60 kg/m2. Grieve et al34 conducted a system-
atic review, which focused on the economic cost of severe 
obesity (BMI ≥40 kg/m2) and found limited literature 
describing increased prescribing, outpatient utilisation 
and intensive care admission, and hospital length of stays 
during critical illness. However, in both studies, there was 
no disaggregation of BMI beyond >40 kg/m2 meaning 
that the health consequences of severe obesity are not yet 
fully described.
There has been extensive research on the relationship 
between HRQoL and obesity.35 Ul- Haq et al36 performed a 
meta- analysis of 8 studies (43 086 participants) and found 
that physical quality of life, measured by the Rand 36- item 
Short Form Health Survey, was reduced by 9.7 points in 
those with a BMI of 40 kg/m2 compared with those with 
a BMI in the normal range, although, again, there was 
no disaggregation above BMI 40 kg/m2. Van Nunen et 
al37 performed a meta- analysis to compare the general, 
non- treatment- seeking population to patients within 
weight management programmes and those seeking 
bariatric surgery. They found that those seeking surgical 
treatment reported the most severely reduced HRQoL, 
perhaps reflecting their reasons for seeking definitive 
surgical treatment. Our cohort of treatment- seeking indi-
viduals who completed a rich battery of patient- reported 
measures provides data to show that health- related and 
obesity- related quality of life of those with the highest 
body mass is extremely poor and this is compounded by 
increasing age. Quality of life scores of SCOTS partici-
pants in both the upper BMI (≥55 kg/m2) and older age 
(≥55 years) groups included physical scores comparable 
with those reported by cancer patients receiving palliative 
care,38 patients with chronic heart failure expressing end 
of life preferences39 and patients with end stage kidney 
disease.40 Furthermore, patients with severe chronic 
obstructive pulmonary disease report higher quality of 
life scores, indicating a better quality of life, than our 
Characteristic
Recruited sample Analysed sample*
N=444 N=249
Current employment 
status, N (%)
Working full time Not collected 124 (50.0)
Working part time 24 (9.7)
Unable to work because of illness or disability 64 (25.8)
Student/unemployed and seeking employment/
unemployed and not seeking employment/
carer/other
36 (14.5)
Missing 1
Working full time: ≥ 30 hours per week; working part time: < 30 hours per week. Percentages may not total 100% in all cases due to rounding.
*Participants who returned baseline questionnaires prior to their bariatric surgery are included in the analysed sample.
BMI, body mass index; SCOTS, SurgiCal Obesity Treatment Study.
Table 1 Continued
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Table 2 Preoperative health- related characteristics of SCOTS participants undergoing bariatric surgery (N=249)
N=249
N (%)
Missing
N (%)
Comorbidity, self- report DVT 8 (3.2) 0
Pulmonary embolism 4 (1.6) 0
Hypertension 107 (43.0) 0
T2D 124 (49.8) 0
Angina/heart attack 17 (6.8) 0
Heart failure 2 (0.8) 0
Stroke/ministroke 6 (2.4) 0
Arthritis 73 (29.3) 0
Back problems 115 (46.2) 0
Chronic bronchitis 4 (1.6) 0
Eczema/psoriasis 33 (13.3) 0
Asthma 70 (28.1) 0
Thyroid problems 32 (12.9) 0
Migraine 49 (19.7) 0
Anxiety/depression 114 (45.8) 0
Kidney disease 7 (2.8) 0
Liver disease 2 (0.8) 0
Cancer 4 (1.6) 0
Irritable bowel syndrome 44 (17.7) 0
Sleep apnoea 66 (26.5) 0
CVD 20 (8.0) 0
N (%), self- reported 
comorbidities
None 9 (3.6) 0
1–2 80 (32.1) 0
≥3 160 (64.3) 0
Gastro- oesophageal reflux Yes 97 (40.4) 9 (3.6)
Female reproductive health, 
N=75*
Mean (SD) age in years, last natural 
menstrual period
39.4 (10.9) 4 (5.3)
Female reproductive health, 
N=177
PCOS, N (%) 28 (16.8) 10 (5.6)
Male reproductive health,
N=72
Impotence, N (%) 28 (41.2) 4 (5.6)
IPSS score ≥8, N (%) 34 (47.9) 1 (1.4)
Incontinence Median (Q1; Q3) ICIQ- UI SF score 4 (0.0; 10.0) 10 (4.0)
ICIQ- UI SF score ≥6 105 (43.9) 10 (4.0)
Incontinence, females,
N=177
ICIQ- UI SF score ≥6, N (%) 83 (49.4) 9 (5.1)
Incontinence, males,
N=72
ICIQ- UI SF score ≥6, N (%) 22 (31.0) 1 (1.4)
Depression Mean (SD) PHQ-9 score 9.6 (6.3) 5 (2.0)
N (%) PHQ-9 score ≥10 107 (43.9) 5 (2.0)
Anxiety Median (Q1; Q3) GAD-7 5 (2.0; 9.0) 6 (2.4)
N (%) GAD-7 score ≥6 114 (46.9) 6 (2.4)
Smoking status Current 13 (5.4) 9 (3.6)
Former 105 (43.8)
Never 122 (50.8)
Alcohol use Median (Q1; Q3) AUDIT 3 (1.0; 6.0) 20 (8.0)
Continued
 on O
ctober 28, 2021 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-046441 on 26 A
ugust 2021. D
ow
nloaded from
 
8 Mackenzie RM, et al. BMJ Open 2021;11:e046441. doi:10.1136/bmjopen-2020-046441
Open access 
cohort of treatment- seeking obese participants.41 As far as 
we are aware, this is the first study to investigate physical 
and mental health in patients with severe obesity awaiting 
bariatric surgery with finer level consideration of a BMI 
up to ≥55 kg/m2.
UK guidelines42 currently indicate that bariatric surgery 
is a treatment option for those with a BMI ≥40 kg/m2, 
or between 35 kg/m2 and 40 kg/m2 in the presence of 
other significant diseases (eg, T2D or hypertension), 
which could be improved if they lost weight. Non- surgical 
weight management must have been attempted but not 
resulted in clinically beneficial weight loss before surgery 
is indicated. However, baseline SCOTS data appear to 
suggest that the low prioritisation of bariatric surgery and 
a lengthy preoperative pathway in the UK is associated 
with surgical treatment being reserved for individuals 
at an older age with a very high BMI. Indeed, in 2018, 
the Global Registry initiative of the International Feder-
ation for the Surgery of Obesity and Metabolic Disorders 
(IFSO) reported a global median pre- bariatric surgery for 
those with a BMI of 41.7 kg/m2,43 as compared with 47.6 
kg/m2 in the SCOTS cohort. Similarly, IFSO reported a 
median patient age of 42 years at the time of bariatric 
surgery,43 as compared with a median age of 47 years for 
SCOTS participants. This combination of higher BMI 
and older age means that, at the time of surgery, Scottish 
N=249
N (%)
Missing
N (%)
Quality of life
SF-12 Mean (SD) PCS 37 (11.4) 13 (5.2)
Mean (SD) MCS 45.5 (10.3) 13 (5.2)
EQ- 5D- 5L Median (Q1; Q3) 0.6 (0.3; 0.8) 12 (4.8)
Mean (SD) VAS 55.3 (22.1) 12 (4.8)
IWQOL- Lite
(standardised scoring)
Mean (SD) physical function 56.9 (25.4) 6 (2.4)
Mean (SD) self- esteem 70.7 (27.1) 7 (2.8)
Mean (SD) sexual life 57.1 (31.7) 18 (7.2)
Mean (SD) public distress 58.1 (27.2) 6 (2.4)
Mean (SD) work 43.6 (29.2) 13 (5.2)
Mean (SD) total score 58.5 (21.7) 7 (2.8)
Life optimism Mean (SD) LOT score 13 (4.9) 14 (5.6)
Physical activity ≥1 walking, moderate or vigorous activity 
in last 7 days
201 (83.4) 8 (3.2)
Median (Q1; Q3) IPAQ score† 720 (40.0; 1800.0) 6 (3.0)
Healthcare utilisations Using any aids or specialist equipment 67 (28.9) 17 (6.8)
Median (Q1; Q3) GP visits in last 3 
months
2 (1.0; 3.0) 79 (31.7)
Median (Q1; Q3) visits to other health/
social care providers in last 3 months
3 (1.0; 5.0) 73 (29.3)
Social security Unable to work due to illness or disability 64 (25.8) 1 (0.4)
Receiving disability living allowance 
(caring)
44 (18.6) 13 (5.2)
Receiving disability living allowance 
(mobility)
47 (19.9) 13 (5.2)
IPSS Scores: 0–7=‘mild symptoms’; 8–19=‘moderate symptoms’; 20–35=‘severe symptoms’.15 ICIQ- UI SF score: ≥6=‘moderate 
incontinence’.16 PHQ-9 scores: 0–4=‘minimal depression’; 5–9=‘mild depression’; 10–14=‘moderate depression’; 15–19=‘moderately severe 
depression’; 20–27=‘severe depression’.20 GAD-7 scores: 0–5=‘mild anxiety’; 6–10=‘moderate anxiety’; 11–15=‘moderately severe anxiety’; 
15–21=‘severe anxiety’.19
*75/177 (42%) female participants reported not menstruating in the last 12 months
†Metabolic equivalent of task min/week.
AUDIT, Alcohol Use Disorders Identification Test; CVD, cardiovascular disease; DVT, deep vein thrombosis; EQ- 5D- 5L, EuroQoL 5- level 
EQ- 5D version; GAD-7, 7- item Generalised Anxiety Disorder Assessment; GP, general practitioner; ICIQ- UI SF, International Consultation 
on Incontinence Questionnaire- Urinary Incontinence Short Form; IPAQ, International Physical Activity Questionnaire; IPSS, International 
Prostate Symptom Score; IWQOL- Lite, Impact of Weight on Quality of Life- Lite; LOT, Life Orientation Test; MCS, Mental Component 
Summary; MET, Metabolic equivalent of task; PCOS, polycystic ovary syndrome; PCS, Physical Component Summary; PHQ-9, Patient Health 
Questionnaire-9; SCOTS, SurgiCal Obesity Treatment Study; T2D, type 2 diabetes; VAS, visual analogue scale.
Table 2 Continued
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patients have high levels of comorbidity and poor physical 
functioning. Bariatric surgery is considered a highly cost- 
effective intervention.44 However, the health economic 
models rely on data primarily from the US and Scan-
dinavian studies,45–49 where BMI and age at the time of 
surgery are lower than in the UK. A higher BMI and older 
age are risk factors for postoperative complications50 51 
and also associated with lower total weight loss.52–54 T2D 
remission rates are negatively correlated with age.55 As 
such, focusing bariatric surgery provision on those with 
older age and higher BMI may result in higher costs of 
surgery with increased length of hospital stay, higher rates 
of postoperative complications, lower overall weight loss 
and lower rates of disease remission. Consequently, the 
impressive health benefits and resultant cost- savings of 
bariatric surgery observed in clinical trials and observa-
tional cohorts from other countries may not be fully real-
ised for the UK/Scottish population.
The SCOTS dataset represents a unique and rich 
resource. A major strength of the study is its represen-
tativeness. Indeed, every clinical team providing publicly 
funded bariatric surgery in Scotland approached their 
patients for recruitment to the study, rendering it highly 
representative of the population in comparison to other 
studies undertaken in the field. However, the number of 
participants with valid baseline questionnaires was lower 
Table 3 Association of age and BMI with QoL, use of specialist equipment in the home and social security
QoL indicators and functional 
measures Variable
Unadjusted models* Adjusted models†
Regression coefficient (95% CI)‡ Regression coefficient (95% CI)‡
SF-12 PCS BMI −4.91 (−6.55 to 3.28) −5.21 (−6.90 to 3.52)
Age −2.44 (−4.03 to 0.85) −2.14 (−3.73 to 0.54)
SF-12 MCS BMI −0.49 (−2.07 to 1.09) −0.40 (−2.06 to 1.26)
Age 0.42 (−1.04 to 1.87) 0.68 (−0.89 to 2.25)
EQ- 5D- 5L score BMI −0.11 (−0.15 to 0.06) −0.11 (−0.16 to 0.06)
Age −0.08 (−0.12 to 0.03) −0.07 (−0.11 to 0.02)
EQ- 5D- 5L VAS BMI −7.08 (−10.38 to 3.79) −7.73 (−11.10 to 4.36)
Age −2.19 (−5.30 to 0.92) −0.65 (−3.77 to 2.46)
IWQOL- Lite physical function BMI 13.72 (10.28 to 17.17) 14.20 (10.69 to 17.70)
Age 5.77 (2.28 to 9.26) 5.01 (1.75 to 8.27)
IWQOL- Lite self- esteem BMI 5.09 (1.02 to 9.16) 5.99 (1.86 to 10.12)
Age −4.74 (−8.51 to 0.97) −5.11 (−8.96 to 1.25)
IWQOL- Lite sexual life BMI 5.56 (0.71 to 10.41) 5.74 (0.82 to 10.67)
Age 3.86 (−0.75 to 8.47) 3.01 (−1.71 to 7.73)
IWQOL- Lite public distress BMI 15.36 (11.72 to 19.00) 16.07 (12.34 to 19.80)
Age −2.78 (−6.57 to 1.02) −3.04 (−6.51 to 0.44)
IWQOL- Lite work BMI 9.54 (5.25 to 13.84) 9.59 (5.16 to 14.02)
Age 1.95 (−2.25 to 6.16) 1.04 (−3.15 to 5.24)
IWQOL total score BMI 10.31 (7.29 to 13.33) 10.88 (7.79 to 13.97)
Age 1.20 (−1.84 to 4.24) 0.55 (−2.33 to 3.43)
Use of aids or specialist 
equipment
BMI 2.34 (1.62 to 3.39)* 3.10 (1.94 to 4.95)*
Age 2.65 (1.76 to 4.00)* 3.10 (1.94 to 4.95)*
Disability living allowance (caring) BMI 1.19 (0.82 to 1.73)* 1.07 (0.72 to 1.59)*
Age 1.54 (1.03 to 2.31)* 1.62 (1.08 to 2.46)*
Disability living allowance 
(mobility)
BMI 1.18 (0.82 to 1.70)* 1.13 (0.77 to 1.65)*
Age 1.64 (1.10 to 2.45)* 1.62 (1.08 to 2.44)*
N ≥10 for all indicators and measures for which regression analyses were performed.
*Unadjusted models, including only the effect of BMI (per 10 kg/m2) or age (per 10 years) on QoL indicators and functional measures
†Adjusted models, including the effects of BMI (per 10 kg/m2) and age (per 10 years) on QoL indicators and functional measures, after 
adjusting additionally for sex, SIMD and smoking status
‡Regression coefficient (95% CI) is estimate (95% CI) for results from the linear regression and OR (95% CI) for results from the logistic 
regression. OR results are indicated with an asterisk mark (*).
BMI, body mass index; EQ- 5D- 5L, EuroQoL 5- level EQ172 5D version; IWQOL- Lite, Impact of Weight on Quality of Life- Lite; MCS, Mental 
Component Summary; QoL, quality of life; SF-12 PCS, 12- item Short Form Survey Physical Component Summary; SIMD, Scottish Index of 
Multiple Deprivation; VAS, Visual Analogue Scale.
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than anticipated. In many cases, this could be attributed 
to the participant undergoing surgery before completing 
the questionnaire, or the participant leaving the bariatric 
surgery pathway before surgery. The overall length of the 
questionnaire may have also played a role. Participants 
living in the most deprived areas were well represented 
in our cohort and the mean quality of life findings were 
broadly similar to those of bariatric surgery cohorts from 
across the world.56–58 A further strength of the study is 
that questionnaires were externally validated and wide 
ranging, containing a number of unique questions 
covering medical, social, psychological and physical func-
tioning domains. This wide range of self- reported health 
measures will allow us to account for a range of potentially 
mediating and confounding factors in future analyses. In 
addition, we have revealed the extent of comorbidities, 
including musculoskeletal, urinary and mental health 
problems affecting people with severe obesity. Low 
numbers of some comorbidities meant that this could not 
be a focus of this analysis.
A limitation of this study is that selection for bariatric 
surgery is often based on the presence of comorbidity; 
so these results, while applicable to a treatment- seeking 
population, may not be directly applicable to the whole 
population with severe obesity in the wider society. While 
we will have access to medical records via electronic health 
record data linkage in follow- up, the current analyses are 
based on self- report of selected comorbidities. It is well 
known that self- reported weights are underreported, 
particularly by people with a very high BMI.59 However, 
we are confident of the accuracy of weight and height 
as these data were collected in clinic during the recruit-
ment visit. With regard to future analyses, follow- up of 
the SCOTS cohort is ongoing, which will allow us to 
report the longitudinal health trajectory after bariatric 
surgery. The electronic health record infrastructure in 
Scotland60 will also permit us to study health outcomes of 
SCOTS participants across a range of clinical events and, 
ultimately, determine the effect of bariatric surgery and 
other factors associated with health outcomes.
Obesity is a multisystem disease which affects every facet 
of a person’s life. Our data have shown that a higher BMI 
combined with older age is associated with very poor phys-
ical functioning, and health- related and obesity- related 
quality of life. Indeed, quality of life scores for those 
living with severe obesity in Scotland are akin to those 
seen in the end stage of diseases such as cancer and heart 
failure. The health consequences of severe obesity and 
the extent to which treatments such as bariatric surgery 
can improve these are not yet known. Researchers should 
ensure that they include people with severe obesity in 
population cohorts and treatment studies, and study the 
impact of severe obesity in more detail; there are substan-
tial differences in the health status of those with a BMI 
above 50 kg/m2 and those whose BMI is around 40 kg/
m2. Policy- makers should consider the health and care 
needs of the growing numbers of individuals living with 
obesity. There will be a considerable future demand for 
healthcare and services must be designed to accommo-
date the physical needs of the individuals. While primary 
prevention of obesity is clearly paramount to avoid more 
people developing such a debilitating, chronic condi-
tion, investment is urgently needed, both in the UK and 
globally, to provide increased access to bariatric surgery 
and other forms of effective weight management, directly 
targeting patient groups who will benefit from surgical 
intervention as early in the disease course as possible.
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Supplementary Table 1. STROBE Statement completed checklist (from von Elm et al.
1
).
SECTION/TOPIC ITEM No. STROBE Recommendation OUR PAPER
Title and 
abstract
1 (a)   Indicate the study’s design with a 
commonly used term in the title or the 
abstract
(a)   See title
(b)   Provide in the abstract an 
informative and balanced summary of 
what was done and what was found
(b)   See abstract
Introduction
Background / 
rationale
2 Explain the scientific background and 
rationale for the investigation being 
reported
Paragraphs 1-3 provide 
background and paragraph 4 
explains rationale
Objectives 3 State specific objectives, including any 
prespecified hypotheses
Paragraph 4
Methods
Study design 4 Present key elements of study design 
early in the paper
Paragraph 3/’Study Design’ 
section
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, and 
data collection
Paragraphs 4-6/ ’Participant and 
Centre Eligibility’, ‘Recruitment 
Procedures and Consent’ and 
‘Data Collection’ sections
Participants 6 (a)   Give the eligibility criteria, and the 
sources and methods of selection of 
participants. Describe methods of 
follow-up
(a)   Paragraphs 4-6/ ’Participant 
and Centre Eligibility’, 
‘Recruitment Procedures and 
Consent’ and ‘Data Collection’ 
sections
(b)   For matched studies, give matching 
criteria and number of exposed and 
unexposed
(b)   Not applicable
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and 
effect modifiers. Give diagnostic 
criteria, if applicable
Paragraphs 7-9/’Data Collection’ 
section
Data sources / 
measurement
8 For each variable of interest, give 
sources of data and details of methods 
of assessment (measurement). Describe 
comparability of assessment methods if 
there is more than one group
Paragraphs 7 and 8/‘Data 
Collection’ section
Bias 9 Describe any efforts to address potential 
sources of bias
Not applicable
Study size 10 Explain how the study size was arrived at Paragraph 4/’Patient and Centre 
Eligibility’ section, paragraph 1 
of ‘Results’ section
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Quantitative 
variables
11 Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen 
and why
 ‘Statistical Analyses’ section
Statistical 
methods
12 (a)   Describe all statistical methods, 
including those used to control for 
confounding
(a)   ‘Statistical Analyses’ section
(b)   Describe any methods used to 
examine subgroups and interactions
(b)   Not applicable
(c)    Explain how missing data were 
addressed
(c)    ‘Statistical Analyses’ section
(d)   If applicable, explain how loss to 
follow-up was addressed
(d)   Not applicable
(e)   Describe any sensitivity analyses (e)   Not applicable
Results
Participants 13 (a)   Report numbers of individuals at 
each stage of study— e.g. numbers 
potentially eligible, examined for 
eligibility, confirmed eligible, included 
in the study, completing follow-up, and 
analysed
(a)   Paragraph 1 and Figure 1
(b)   Give reasons for non-participation 
at each stage
(b)   Paragraph 1 and Figure 1
(c)    Consider use of flow diagram (c)    Figure 1
Descriptive data 14 (a)   Give characteristics of study 
participants (e.g. demographic, clinical, 
social) and information on exposures 
and potential confounders
(a)   Paragraphs 2-
5/’Characteristics of recruited 
and analysed sample’, 
‘Comorbidities’, “Health and 
obesity-related quality of life’ 
and physical activity’ sections, 
Table 1 and Table 2
(b)   Indicate number of participants 
with missing data for each variable of 
interest
(b)   Paragraphs 2-7, Table 1, 
Table 2, Supplementary Table 2 
and Supplementary Table 3
(c)    Summarise follow-up time (e.g. 
average and total amount)
(c)    Not applicable
Outcome data 15 Report numbers of outcome events or 
summary measures over time
Table 2, Supplementary Table 2 
and Supplementary Table 3
Main results 16 (a)   Give unadjusted estimates and, if 
applicable, confounder-adjusted 
estimates and their precision (e.g. 95% 
confidence interval). Make clear which 
confounders were adjusted for and why 
they were included
(a)   Table 3 and Supplementary 
Table 4
(b)   Report category boundaries when 
continuous variables were categorised
(b)   Supplementary Table 4
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(c)    If relevant, consider translating 
estimates of relative risk into absolute 
risk for a meaningful time period
(c)    Not applicable
Other analyses 17 Report other analyses done e.g. analyses 
of subgroups and interactions, and 
sensitivity analyses
Not applicable
Discussion
Key results 18 Summarise key results with reference to 
study objectives
Paragraph 1
Limitations 19 Discuss limitations of the study, taking 
into account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias
Paragraph 5
Interpretation 20 Give a cautious overall interpretation of 
results considering objectives, 
limitations, multiplicity of analyses, 
results from similar studies, and other 
relevant evidence
‘Conclusion’
Generalisability 21 Discuss the generalisability (external 
validity) of the study results
Paragraph 5
Other 
informationFunding 22 Give the source of funding and the role 
of the funders for the present study and, 
if applicable, for the original study on 
which the present article is based
‘Funding’ section
Reference
1) von EE, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting 
observational studies. Lancet  2007; 370(9596): 1453-1457
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Date Protocol version Amendment number & description 
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15/04/2013 1.1 Amendment 1: Minor changes to the 
format and presentation of the 
protocol 
11/07/2013 1.2 Amendment 2:   Correction of 
typographical errors in the protocol 
30/06/2014 1.3 Amendment 3: Change to recruitment 
process for private hospitals involved 
in the study. Private hospitals will now 
become participant identification sites 
(and any NHS sites which in future are 
unable to support local recruitment), 
with participants being recruited and 
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consented by a research team 
member (usually a research nurse).  
 
03/06/2015 1.4 Amendment 4: Introduction of follow-
up letter for patients recruited over 
the telephone by research nurses at 
the clinical research facility if 
completed consent form is not 
received within two weeks.  
 
07/02/2017 1.5 Amendment 5; Revised study plan 
(including timetable & outputs). 
Patient recruitment stopping at a 
lower number and earlier than 
originally planned due to unforeseen 
recruitment issues.  Amendment to 
clinical objectives and outcomes to 
reflect smaller sample size and shorter 
follow-up period. Reduction of post-
operative questionnaire frequency to 
2 and 3 years post-operatively only. 
Introduction of modest voucher 
incentives for PROMS completion. 
22/11/2017 1.6 Amendment 6; Removal of annual 
blood test reminder.  This procedure is 
completed as part of the routine 
clinical care by the patient’s GP and 
therefore, it is not necessary for a 
reminder to be sent in addition for the 
SCOTS study. 
 
 
This study will be performed according to the Research Governance Framework for Health 
and Community Care (Second edition, 2006) and WORLD MEDICAL ASSOCIATION 
DECLARATION OF HELSINKI  Ethical Principles for Medical Research Involving Human 
Subjects 1964 (as amended). 
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STUDY SYNOPSIS 
 
Title of Study: Surgical Obesity Treatment Study; SCOTS 
Study Centre: University of Glasgow 
Duration of Study: 03/01/2012 – 30/06/2026 
Primary Objective: The SurgiCal Obesity Treatment Study (SCOTS) will 
establish the clinical outcomes and adverse events of 
different bariatric surgical procedures (taking into 
consideration the different care pathways), their impact on 
quality of life and nutritional status, and the effect on co-
morbidities in a cohort of 450 patients. 
Secondary Objectives: 1. The physical and mental health and social burden of 
severe obesity. 
2. Incidence of acute and chronic postoperative 
complications.  Acute complications, defined as up to 
three months post-surgery, will include surgical site 
infection; chronic complications will include revisional 
surgery, plastic surgery and chronic pain, for different 
bariatric surgical procedures 
3. The effect of surgical experience and the pre and post-
operative care pathway on complication rates and 
weight loss, for different bariatric surgical procedures. 
4.   The effect of the pre-surgical pathway and criteria on 
bariatric surgery patient selection.   
5. Change in health related quality of life, anxiety and 
depression over time pre- and post-operatively for a 
mean of 3 years from date of bariatric surgery.   
6. The weight status pre and post-operatively for 3 years 
after bariatric surgery. 
7. The glycaemic control, lipids, blood pressure, 
medication prescription, and rate of diabetes 
complications (microalbuminuria and renal disease, 
and retinopathy) in those that have pre-existing 
diabetes or develop diabetes for 3 years follow up 
since bariatric surgery. 
8. Changes in socio-economic factors (employment, 
benefit receipt, sick leave, and health care use) for 3 
years since bariatric surgery. 
 
 
Primary Endpoint:  Change in weight from pre-bariatric surgery weight  
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Rationale: The efficacy of bariatric surgery for large scale, long term 
weight loss is well established. However, many questions 
remain over the medium term benefits of that weight loss 
for health, particularly when accounting for the potential 
complications of surgery. 
Methodology: Observational cohort study/ registry 
Sample Size: 450 
Screening: All new bariatric surgery patients 
Registration/Randomisation: Not applicable 
Main Inclusion Criteria: • Patients 16 years or over undergoing their first 
bariatric surgery in NHS hospitals or private practice 
in Scotland. 
• Capacity to consent 
• Resident in Scotland 
• Written informed consent 
Main Exclusion Criteria: • Does not meet inclusion criteria  
• Patients who have had previous weight loss surgery 
(at time of potential recruitment are undergoing a 
repeat procedure) 
• No written informed consent 
• Patients under 16 years 
• Patients who do not have capacity to consent for 
themselves 
• Weight loss surgery performed at a site outside 
Scotland 
• Patients who live outside Scotland 
• Patients who do not have strong enough English 
language skills to understand the patient information 
leaflet without assistance will be excluded from Part 
2 of the study. 
Product, Dose, Modes of 
Administration:  
Web based or paper questionnaire to be completed  
1 month pre-surgery 
2 years post surgery 
3 years post surgery 
Duration of Treatment: Observational study so protocol will be applied until a 
participant has been in study for 3 years or until December 
2020 whichever comes first. If funding available record 
linkage will continue throughout patient’s life.  
Statistical Analysis: Detailed statistical analysis plans will be developed by the 
Robertson Centre for Biostatistics to address each of the 
objectives described above. 
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GLOSSARY OF TERMS 
 
Bariatric Surgical Procedures: A bariatric surgical procedure is defined as a surgical 
intervention which has the primary purpose of large scale weight loss in a patient who is 
obese. Bariatric Surgical procedures eligible for inclusion in SCOTS are: duodenal switch, 
gastric banding, gastric bypass and sleeve gastrectomy. The inclusion of emerging 
techniques in this definition will be decided by the steering committee. 
Biliopancreatic diversion with duodenal switch (BPD-DS): see Duodenal Switch: 
Body mass index (BMI) is a simple index of weight-for-height that is commonly used to 
classify overweight and obesity in adults. It is defined as a person's weight in kilograms 
divided by the square of his height in meters (kg/m2). BMI provides the most useful 
population-level measure of overweight and obesity as it is the same for both sexes and for 
all ages of adults. However, it should be considered a rough guide because it may not 
correspond to the same degree of fatness in different individuals. 
Co-morbidity: is either the presence of one or more disorders (or diseases) in addition to a 
primary disease or disorder, or the effect of such additional disorders or diseases. 
Duodenal Switch: (DS) is a weight loss surgery procedure that is composed of a restrictive 
and a malbsorbative aspect. The restrictive portion of the surgery involves removing 
approximately 70% of the stomach along the greater curvature. The malabsorptive portion of 
the surgery reroutes a lengthy portion of the small intestine, creating two separate pathways 
and one common channel. Duodenal switch (DS) is also known as biliopancreatic diversion 
with duodenal switch (BPD-DS) or gastric reduction duodenal switch (GRDS). 
Endoluminal barrier: is a liner that fits inside a section of the intestine, creating a barrier 
between the intestinal wall and the food you eat. It helps patients to lose weight by 
preventing food from coming into contact with the intestinal wall thus delaying digestion, 
which will alter the activation of hormonal signals that originate in the intestine. 
Gastric balloon: An inflatable device implanted in the stomach as an adjunct to therapy of 
morbid obesity. For the purposes of the SCOTS study a balloon treatment is not considered to 
be bariatric surgery. Use of a balloon before or after surgery will be recorded as a pre-
operative treatment but a balloon alone would not meet the criteria for inclusion in SCOTS.  
Gastric band: adjustable gastric banding surgery, is a restrictive weight loss surgery that 
works by decreasing the amount of food that is able to be consumed before feeling full. 
During gastric banding surgery, a firm silicone band with an inner inflatable ring is placed 
around the stomach to slow the passage of food from the upper portion of the stomach to 
the lower portion 
Gastric bypass: a surgical bypass operation that typically involves reducing the size of the 
stomach and reconnecting the smaller stomach to bypass the first portion of the small 
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intestine so as to restrict food intake and reduce caloric absorption in cases of severe obesity. 
This includes Gastric bypass, Roux en-Y (proximal), Gastric bypass, Roux en-Y (distal) and 
Mini-gastric bypass" (MGB) 
Gastric reduction duodenal switch (GRDS): see duodenal switch 
Glycaemic control: is a medical term referring to the typical levels of blood sugar (glucose) in 
a person with diabetes mellitus. Much evidence suggests that many of the long-term 
complications of diabetes, especially the microvascular complications, result from many 
years of hyperglycemia (elevated levels of glucose in the blood). 
Hemoglobin A1c (HbA1c): Blood sugar levels fluctuate throughout the day and glucose 
records are imperfect indicators of these changes, the percentage of haemoglobin which is 
glycosylated is used as a proxy measure of long-term glycemic control in research trials and 
clinical care of people with diabetes. This test, the hemoglobin A1c or glycosylated 
hemoglobin reflects average glucoses over the preceding 2–3 months. From 1 October 2011 
the way in which HbA1c results are expressed in the UK has changed. Results are now 
reported in the IFCC reference method of mmol/L, rather than the DCCT units as a 
percentage. The equivalent of the current HbA1c targets of 6.5% and 7.5% are therefore 
48mmol/mol and 58mmol/mol in the new units for diabetic patients, with the non-diabetic 
reference range of 4.0% to 6.0% being 20mmol/L to 42mmol/L. 
HDL cholesterol: High density lipoprotein cholesterol. Lipoproteins, which are combinations 
of fats (lipids) and proteins, are the form in which lipids are transported in the blood. HDLs 
transport cholesterol from the tissues of the body to the liver, so the cholesterol can be 
eliminated in the bile. HDL cholesterol is therefore considered the 'good' cholesterol: The 
higher the HDL cholesterol level, the lower the risk of coronary artery disease. The average 
man has an HDL cholesterol level of 40 to 50 mg/dL. In the average woman, HDL levels range 
from 50 to 60 mg/dL. 
Health Technology Assessment: is a multidisciplinary process that summarises information 
about the medical, social, economic and ethical issues related to the use of a health 
technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the 
formulation of safe, effective, health policies that are patient focused and seek to achieve 
best value. 
Hypertriglycerideamia: denotes high (''hyper-'') blood levels (''-aemia'') of triglycerides, the 
most abundant fatty molecule in most organisms.  
Laparoscopic gastric banding: Lap Band surgery, or adjustable gastric banding surgery, is a 
restrictive weight loss surgery that works by decreasing the amount of food that is able to be 
consumed before feeling full. During gastric banding surgery, a firm silicone band with an 
inner inflatable ring is placed around the stomach to slow the passage of food from the 
upper portion of the stomach to the lower portion. Most surgeries are performed 
laparoscopically, which allows the surgeon to work using long instruments placed in the body 
via incisions a few centimetres long. 
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Laparoscopy: is a type of surgical procedure that allows a surgeon to access the inside of the 
abdomen and pelvis without having to make large incisions in the skin. It is also known as 
keyhole surgery. Laparoscopy is minimally invasive. This is made possible with an instrument 
called a laparoscope. 
Morbidity: Morbidity is an incidence of ill health. 
Mortality: is incidence of death in a population. 
NHS patient: A patient who receives free healthcare through the National Health Service 
Nutritional Status: The state of a person’s health in terms of the nutrients stored in his or her 
body. 
Obesity: Obesity is a term used to describe somebody who is very overweight with a high 
degree of body fat. There are a number of ways a person’s weight can be assessed. The most 
widely used method is the body mass index. 
Overweight: a BMI of between 25 and 29, would be considered overweight  
Obese: a BMI of 30 or above would be considered obese  
Private sector: healthcare and medicine provided by entities other than the government and 
paid for by the patient or a private insurance company. 
Prospective cohort study: a study designed to determine the relationship between a 
condition and a characteristic shared by some members of a group. The population selected 
is healthy at the beginning of the study. Members share a particular characteristic. The study 
follows the population groups over a long period, noting the rate at which a condition occurs 
in the population. 
Revisional surgery: a bariatric surgical procedure on a patient who has already had bariatric 
surgery 
Roux-en-Y gastric bypass:  a small part of the stomach is used to create a new stomach 
pouch, roughly the size of an egg. The smaller stomach is connected directly to the middle 
portion of the small intestine (jejunum), bypassing the rest of the stomach and the upper 
portion of the small intestine (duodenum). 
Sleeve gastrectomy: is a surgical weight-loss procedure in which the stomach is reduced to 
about 25% of its original size, by surgical removal of a large portion of the stomach, following 
the major curve. The open edges are then attached together (often with surgical staples) to 
form a sleeve or tube with a banana shape. The procedure permanently reduces the size of 
the stomach. The procedure is performed laparoscopically and is not reversible. 
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STUDY FLOW CHART 
 
FIGURE 0-1 THIS STUDY FLOW CHART SUMMARISES THE PATIENT JOURNEY TRHOUGHOUT THE STUDY 
Patient invited to participate in SCOTS study
Provided with information leaflet 
Patient agrees to proceed with bariatric surgery 
Patient returns to hospital to discuss bariatric surgery
Investigator asks patient if they fulfil eligibility 
criteria (or asks permission to pass details to 
research team and research team member 
contacts patient to seek consent) and are 
willing to consent to participate in SCOTS 
and  discusses any concerns
Patient signs consent 
form Yes
Consent forms 
filled and 
recruitment form 
posted to 
Robertson Centre 
Yes
Patient contacted by Robertson Centre 
and asked to complete Patient 
questionnaires 
Patient undergoes bariatric 
surgery
Details of operative 
procedure included in 
SCOTS database by local 
investigators 
No
Patients consented to Part 2
Patients consented 
to part 1
Routine clinical 
care not contacted 
again
Patients not consented to part 1
Clinical team enter all patients 
anonymised screening data in 
screening log
Baseline details 
recorded on 
recruitment form 
by investigators
Patient contacted to 
complete patient 
questionnaire 2 years, 3 
years
Patients details linked to 
SMR data, SCI DC and 
SCI Store
Visit 1
Invitation visit
(part of normal 
care pathway)
Visit 2 
Consent visit (part 
of normal care 
pathway)
Bariatric Surgery 
(part of normal 
care pathway)
Routine clinic 
visits and re-
operation
Contacted by 
SCOTS team to 
arrange pre-
operative 
questionnaire 
completion
Regular contact 
with SCOTS team 
by patients 
preferred 
communication 
route 
(email,or letter) 
Record linkage by 
SCOTS study 
team for 
consented 
patients
This requires no 
action from 
patients
END
Patient fulfills criteria for consideration of 
bariatric surgery
No
Patient follow up 
weights and re-
operation details 
recorded by 
clinical teams
Patients consented 
to part 2
Patients not consented 
to part 2
Patients consented to 
part 3 contacted 
throughout study to 
participate in other 
studies
Patients consented to Part 1 only
Yes
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SCHEDULE OF ASSESSMENTS 
TABLE 0-1: THIS SCHEDULE SHOWS EACH EVENT THAT INVOLVES THE PATIENT AND STUDY TEAM.  
 Pre-surgery  Post 
surgery 
SCOTS 
Questio
nnaires  
Study Procedure  Pre-surgery 
Visit 1 
1 year to 
six weeks 
before 
surgery 
Pre-surgery 
Visit 2 
1 year to 
six weeks 
before 
surgery 
Pre-
surgery 
Contact1 
Pre-
surgery 
Contact2 
Surgery 
T0 
2yr 3yr 
Patients agree to proceed to 
bariatric surgery with clinical 
team 
√       
Review Inclusion/Exclusion 
Criteria 
√a       
Patients provided with patient 
information sheet 
√       
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Patient data entered onto 
screening log for SCOTS 
 √      
Patient return for pre-surgery 
clinic 
 √      
Clinical team ask permission from 
patients to pass details to 
research team who will contact 
patient (if not recruiting in local 
site) 
 (√)      
Obtain Informed Consent to 
participate in SCOTS study 
 √      
Patient baseline and contact 
details entered on registration 
form and sent to Robertson 
Centre for Biostatistics  
 √      
Consent form passed filed in Site 
File, copy given to patient and 
copy sent to RCB 
 √      
Contacted by SCOTS team to ask 
to complete pre-surgery 
questionnaire 
  √     
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Patient completes pre-surgery 
questionnaire  
   √    
Patient undergoes bariatric 
surgery 
    √   
Clinical teams record operative 
details for patient post surgery 
    √   
Clinical teams record weight and 
re-operation details  
     √ √ 
Patients contacted to remind 
them to complete post surgery 
questionnaire  
     √ √ 
Part 3 consented patients may be 
invited to participate in other 
studies 
Ongoing throughout study 
Record linkage to SCI-Store, SCI –
DC, SMR (ISD), GRO throughout 
study 
Ongoing throughout study, no interaction with patient unless to 
clarify if admission was a complication of bariatric surgery. 
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1 INTRODUCTION 
 
1.1 Background 
 
SCOTS is a prospective cohort study commissioned by the Department of Health (DoH) 
National Institute of Health Research (NIHR) which will follow bariatric surgery patients for 3 
years after their surgery. The NIHR commissioning brief for this study stated: “Obesity is a 
growing problem in the United Kingdom, with a growing number of people among the 
morbidly obese. Concomitantly, there is an increase in requests for bariatric surgery but 
insufficient evidence of long term effectiveness and safety of these procedures. There are 
existing registries of bariatric surgery, but these suffer from problems of collected data, 
completeness of follow- up, or data availability for secondary analysis. There is a need for a 
long term study of bariatric surgery, so that the outcomes and complications of different 
procedures, their impact on quality of life and nutritional status, and the effect on co-
morbidities can be monitored in both the short and the long term.” A recent Health 
Technology Assessment (HTA) (1) concluded that “Bariatric surgery is a more clinically 
effective intervention for treating obesity compared to non-surgical options” however they 
qualified this with “Uncertainties remain over the long-term outcomes of bariatric surgical 
interventions, particularly their impact on weight-related health problems and patient 
quality of life. Further studies will be required”. This study was awarded NIHR HTA funding to 
address some of the uncertainties around the clinical effectiveness of bariatric surgery in the 
longer term.   The original plan included a 10 year follow up period, however, due to 
unforeseen recruitment issues (reductions in both NHS & private surgical numbers) the 
study & statistical plans were reviewed.  Following discussions with the NIHR it was agreed 
that many objectives could still be met from the number of patients currently recruited over 
a shorter period of follow up (3 years). The protocol has been updated to reflect these 
changes. Clearly some patients will have completed the 1 month, 6 month and 1 year post-
operative questionnaire already. Where appropriate, these data will be used to supplement 
the year 2 and 3 questionnaires and the health record data in order to deliver the study 
objectives.  
1.2 Rationale 
 
The efficacy of bariatric surgery for large scale, long term weight loss is well established (2). 
However, many questions remain over the medium term benefits of that weight loss for 
health, particularly when accounting for the potential complications of surgery. Given that 
the proportions of the population who are obese is increasingly rapidly, further information 
is required as to who benefits most from bariatric surgery. 
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1.2.1 Definition of bariatric surgery 
 
A bariatric surgical procedure is defined as a surgical intervention which has the primary 
purpose of large scale weight loss in a patient who is obese. Currently that includes gastric 
bypass, sleeve gastrectomy and laparoscopic gastric banding. The inclusion of emerging 
techniques in this definition will be decided by the SCOTS Steering Committee (SCC). 
 
1.2.2 Clinical Outcomes of weight loss surgery 
 
There are some pre-existing data on clinical outcomes with 10 year mortality rates being the 
best known. Overall mortality was found to be 29-40% lower in patients receiving bariatric 
surgery compared to Body Mass Index (BMI)-matched subjects not receiving surgery (3;4).  
Although impressive, these figures are from studies which initially recruited in the 1980s and 
early 1990s and further work is required to update the mortality rate in the current 
population, now that primary prevention measures for cardiovascular disease, such as 
statins and ACE-inhibitors, have lowered the risk of premature mortality in at risk subjects, 
including those who are obese or have diabetes.  
Diabetes improvement post bariatric surgery has also been of interest. Dixon et al conducted 
a randomised controlled trial of laparoscopic gastric banding in patients with newly 
diagnosed type 2 diabetes resulted in a 73% remission rate after 2 years (5). Similar results 
have been shown for gastric bypass using meta-analysis of heterogeneous, mainly 
retrospective, cohort studies (6). Whether remission is maintained beyond the first few 
years post surgery is unknown. However, the main outcomes of interest are the longer term 
effects on the development of diabetes complications such as retinopathy, nephropathy and 
cardiovascular disease and those are not established. 
The effect of bariatric surgery on cardiovascular outcomes has not been ascertained. It is 
known that HDL cholesterol is less likely to be low and hypertriglycerideamia is less common 
after surgery (7), as expected by a procedure which will reduce intra-abdominal adiposity 
and thus insulin resistance, but a reduction in cardiovascular events has not been shown. 
Hypertension, which would be presumed to decrease, in fact shows no difference 8 years 
post surgery, once the initial antihypertensive effects of acute weight loss in the first few 
years post-surgery are accounted for (8). Many have used cardiovascular risk factors 
measured during the acute weight loss phase, applied a population based cardiovascular risk 
score and stated a reduction in cardiovascular risk; this is of course a flawed use of such a 
score based on temporarily reduced cardiovascular risk factors. So, while the general 
population and the majority of physicians may assume that weight loss with bariatric surgery 
reduces the risk of a cardiovascular event, this is currently unknown. 
What is established is that health related quality of life (HR-QoL) is increased compared to 
pre-operative levels (9). When patients who decide to proceed to surgery are compared to 
those who opt for non-surgical treatment only, the baseline HR-QoL is far lower in those 
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who select surgery, showing at least a perception of reduced quality of life in these 
individuals (10). To what extent the improvements seen in HR-QoL correlate with weight 
loss, complications and clinical outcomes is not known. 
The complication rates of bariatric surgery are poorly reported in the literature, leading to 
polarised views on their true incidence. Mortality rates in the first year post surgery have 
been reported as being similar to those of BMI-matched controls (11); however, the same 
results may not be found today due to the decreased mortality rates as a result of primary 
preventative. There is little report of specific wound complications and re-operation rates, 
with a general belief that the low rates reported by the few studies releasing this data would 
not be replicated in routine practice. 
1.3 Study hypothesis 
 
This study is a registry of bariatric surgery and is therefore the study design is based on 
objectives but not hypotheses. 
2 STUDY OBJECTIVES 
 
SCOTS is a prospective observational cohort study of 450 patients undergoing bariatric 
surgery in Scotland which will be used to assess medium term outcomes and complications 
of bariatric surgery. This is in order to identify risks and complications of bariatric surgery 
and develop an evidence base to support clinical teams in building a patient centred, safe, 
effective and efficient bariatric surgery service. 
2.1 Primary Objective 
 
The SurgiCal Obesity Treatment Study (SCOTS) will establish the clinical outcomes and 
adverse events of different bariatric surgical procedures (taking in to consideration different 
care pathways), their impact on quality of life and nutritional status, and the effect on co-
morbidities in a cohort of 450 patients. 
2.2 Secondary Objectives 
 
To establish in a cohort of obese patients who are undergoing bariatric surgery: 
1. The physical and mental health and social burden of severe obesity.  
2. Incidence of acute and chronic postoperative complications.  Acute complications, 
defined as up to three months post-surgery, will include surgical site infection; 
chronic complications will include revisional surgery, plastic surgery and chronic 
pain, for different bariatric surgical procedures.   
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3. The effect of surgical experience and the pre and post-operative care pathway on 
complication rates and weight loss, for different bariatric surgical procedures.   
4. The effect of the pre-surgical pathway and criteria on bariatric surgery patient 
selection.  Change in health related quality of life, anxiety and depression over time 
pre- and post-operatively for a mean of 3 years from date of bariatric surgery.   
5. The weight status pre and post-operatively for 3 years after bariatric surgery. 
6. The glycaemic control, lipids, blood pressure, medication prescription, and rate of 
diabetes complications (microalbuminuria and renal disease, and retinopathy) in 
those that have pre-existing diabetes or develop diabetes for 3 years follow up since 
bariatric surgery. 
7. Changes in socio-economic factors (employment, benefit receipt, sick leave, and 
health care use) for 3 years since bariatric surgery. 
All the above objectives are due to be achieved by December 2020 (Start Jan 2012, 2 years 
development, 3 years recruitment finishing March 2017, mean 3 years post-operative 
follow-up finishing December 2020). 
2.3  Primary Outcome 
 
Change in weight from pre-bariatric surgery weight. 
 
2.4 Secondary Outcomes 
 
1.  Incidence of physical and psychological comorbidity in a population seeking bariatric 
surgery 
 
In the 3 years following bariatric surgery: 
2. Change in weight/BMI from pre-bariatric surgery weight  
3. Rate of incident type 2 diabetes 
4. Change in incidence of depression and anxiety compared to baseline level pre-
operatively 
5. Incidence of complications immediately post-operatively and the need for 
readmission for revisional procedures 
6. Change in health-related quality of life compared to baseline level pre-operatively 
7. Change in glycaemic control, cardiovascular risk factors, CKD, retinopathy and 
medications prescribed in patients with diabetes compared to equally obese patient 
with diabetes who did not have bariatric surgery 
8. Cost of the procedure and follow-up  
 
Outcomes, including their source and frequency of measurement, are summarised in table 1. 
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3 STUDY DESIGN 
3.1 Overview of study design 
 
This 3 year prospective cohort study will collect data on the medium term outcomes of 
bariatric surgery in a minimum of 400 individuals. The study will be performed according to 
the Research Governance Framework for Health and Community Care (Second edition, 2006) 
(12). The information required to meet the objectives will be collected by a combination of 
sources including: bariatric surgery specific information entered by clinical teams; data 
linkage to routine clinical data and patient reported outcome measure questionnaires 
(PROMS). The outcomes and the data source are described in detail in Table 3-1. 
TABLE 3-1: PRIMARY AND SECONDARY OBJECTIVES OF SCOTS DESCRIBING SOURCES OF OUTCOME DATA  
 Outcome Data source Frequency 
1 Incidence of physical and 
psychological comorbidity in a 
population seeking bariatric 
surgery.   
SCI-DC Scottish National 
dataset, eDRIS at 
National Service 
Scotland, Patient 
reported 
questionnaires. 
Continuous throughout 
study 
2.1 Change in weight/BMI from pre-
bariatric surgery 
Clinical teams At recruitment, annual 
check up  
2.2 Rate of incidence of type 2 diabetes SCI-DC Scottish National 
dataset 
Continuous throughout 
study 
2.3 Change in incidence of depression 
and anxiety compared to baseline 
levels pre-operatively 
eDRIS at National 
Service Scotland, 
Patient reported 
questionnaires  
Pre-operatively, ,2,3 
years post operatively 
 
2.4 Incidence of complications 
immediately post-operatively and 
the need for revisional procedures 
Patient reported 
questionnaires, surgical 
teams 
Pre-operatively, 2, 3 
years post operatively, 
at time of re-operation. 
2.5 Change in health related quality of 
life compared to baseline 
Patient reported 
questionnaires  
Pre-operatively, 
2,3years post 
operatively 
2.6 Change in glycaemic control, 
cardiovascular risk factors, chronic 
kidney disease (CKD), retinopathy, 
medications in patients with 
SCI-DC Scottish National 
dataset 
Pre-operatively, 2, 3 
years post operatively, 
at time of re-operation. 
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diabetes compared with non-obese 
cohort 
2.7 Cost of the procedure and follow-
up (to inform cost effectiveness 
analysis) 
Clinical teams, e-
prescribing record 
linkage, patient 
reported outcomes  
At time of patients 
operation, continuous 
linkage throughout the 
study 
 
This protocol describes the objectives of the study, the sources of data collection for each 
objective, and the input required from patients and clinical teams throughout the study. A 
data collection portal will be developed for the study with secure logins for clinical teams 
and participating patients. A detailed user manual will be developed for the operation of this 
system will be produced by the Robertson Centre for Biostatistics - University of Glasgow.  
A SCOTS web based portal will be developed which will present information on the study to 
the public and other researchers. The portal will contain secure logins to the Robertson 
Centre databases which will allow clinical teams to enter data. Clinical teams will be asked to 
register for a user ID and password. These will be issued once the team have undergone the 
necessary training for their delegated role. Everyone who has a user ID and login will be a 
member of the SCOTS investigators group.  
The SCOTS portal will include an area which will allow patients who have agreed to complete 
the patient questionnaires to login securely and complete the patient reported outcome 
questionnaires. If patients prefer to complete the questionnaires on paper the data will be 
entered by staff at the Robertson Centre into the database. Patients will be kept up to date 
with progress of the study via updates on the study website. Patients will be sent reminders 
through their preferred route of communication to let them know when they are due to 
complete a questionnaire.  
Patient identifiable information will be stored separately from the clinical outcome data. The 
information will be linked using a database code. Within the Robertson Centre individuals 
who can access patient information to send reminder letters will not have access to any 
clinical information. Any clinical information to be analysed will have all patient contact 
details remove. Production of any reports will follow the NHS Information and Statistics 
division (ISD) Statistical Disclosure Control protocol (13) to ensure that patient confidentially 
is maintained, (this is a requirement of the record linkage arrangement with ISD).  
SCOTS has three distinct parts. All adult patients who are having weight loss surgery in 
Scotland will be invited to participate in three parts of the study. These parts are described 
in detail below.  
 
 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046441:e046441. 11 2021;BMJ Open, et al. Mackenzie RM
Glasgow Clinical Trials Unit 
Surgical Obesity Treatment Study 
2017_11_22 SCOTS Protocol v1.6  Page 29 of 61 
3.1.1 Part 1 Record Linkage 
 
The study will collect data by record linkage to patients’ clinical outcomes. Information will 
be recorded by the clinical team on the operation they have had. They will be followed using 
their medical records until at least December 2020 and if funding is available for the rest of 
their life.  This will include all hospital admissions, blood test results, diagnostic test results, 
diabetes complications, medications they are prescribed, pregnancy, psychiatry and 
mortality. This part of the study will observe patients care. The study will not alter their 
planned care in any way. No additional tests or treatments will be given to patients who 
consent to be part of the study. (This will fulfil the primary objective and objectives 1, 2, 3 
and 4). If patients do not consent to participate in this part of the study they will not be 
asked to participate in Part 2 or Part 3.  
Each record linkage requires approvals to access data including a favourable ethical opinion. 
These will be sought by the SCOTS Project team. A separate procedure for each data linkage 
will be developed by the Robertson Centre for Biostatistics. Patient identifiable information 
is required to identify study participants. The information required is patient CHI number, 
family name, given name, patient date of birth, gender, postcode, consent data and unique 
study identifier.  
 
3.1.2 Part 2 Patient Reported Outcomes (PROMS) Questionnaire 
 
We will ask patients if they are willing to complete a questionnaire which will include 
questions on quality of life, overall health and fitness, diet, and anxiety and depression, 
healthcare utilisation and ability to work. They will also be asked about problems they may 
have experienced since their surgery such as pain and surgical site infection post discharge.).  
Where patients are not completing PROMS and there is no reliable clinical weight record, we 
will write after 3 years requesting completion of a weight questionnaire (simply asking their 
current weight). The patients will be offered a voucher based incentive of £30 for completing 
both the year 2 and 3 questionnaires (high street voucher), and £10 for the year 3 weight 
follow-up questionnaire (for those no longer in clinical follow-up/not completing PROMS) 
 
3.1.3 Part 3: Registration for a database of bariatric patients for future 
research 
 
Patients who have agreed to Parts 1 and 2 will be asked if they are willing to be contacted 
about possibly taking part in other studies. This will not be an obligation to take part, just an 
expression of interest in being invited to take part. This will create a database of patients 
who have had bariatric surgery and are willing to consider participation in future research. 
Ethical opinion will be sought for the development of these study protocols.  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046441:e046441. 11 2021;BMJ Open, et al. Mackenzie RM
Glasgow Clinical Trials Unit 
Surgical Obesity Treatment Study 
2017_11_22 SCOTS Protocol v1.6  Page 30 of 61 
 
3.1.4 Service user involvement 
 
SCOTS will uphold the principles embodied by NIHR INVOLVE in relation to user involvement 
in research, to provide training and support, negotiated roles, time and equitable access for 
service users involved in this study. SCOTS recruited a patient focus group made of service 
users who have undergone different procedures both in NHS and private healthcare.  
The SCOTS patient focus group have commented on the design of the study, in particular by 
providing advice on the acceptability of the patient reported outcome questionnaires, the 
burden to patients and on material and resources that will be given to potential participants. 
Future sessions are planned to discuss patient recruitment and retention strategies. SCOTS 
have included a service user on the SCOTS Steering Committee.   
3.2 Study Population 
 
All patients due to have a bariatric surgical procedure in Scotland will be invited to 
participate - both NHS and private sector.  
A bariatric surgical procedure is defined as a surgical intervention which has the primary 
purpose of large scale weight loss in a patient who is obese. Currently those procedures 
include:  duodenal switch; gastric banding; gastric bypass and sleeve gastrectomy. The 
inclusion of emerging techniques in this definition will be decided by the steering 
committee. 
 
3.3 Reference populations 
 
Within this protocol the objectives will be met by comparing before and after surgery 
outcomes for the SCOTS cohort. Additional funding shall be sought to develop protocols to 
allow comparisons with the following groups for a final Health Technology Assessment 
report.  
1. SCOTS will compare outcomes with the IT based non-surgical weight management 
database in Greater Glasgow and Clyde (treatment seeking population with current data on 
10,000 patients and 3,000 new referrals per year) which has prospective consent for 
research allowing data linkage for morbidity and mortality along with adjustment for 
smoking, deprivation, BMI, age and sex. 
2. Standardised mortality ratios are available for a BMI matched cohort from the 
Scottish Health Survey. 
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3. The Scottish diabetes database allows an anonymous control group matched for key 
demographics to be created with prospective follow up of diabetes care and complications, 
compared to those with diabetes who had bariatric surgery. 
 
3.4 Inclusion criteria 
 
• Patients aged 16 years or over undergoing their first bariatric surgery in NHS hospitals 
or private practice in Scotland. 
• Capacity to consent 
• Resident in Scotland 
• Written informed consent 
3.5 Exclusion criteria 
 
• Does not meet inclusion criteria  
• Patients who have had previous weight loss surgery (at time of potential recruitment are 
undergoing a repeat procedure) 
• No written informed consent 
• Patients under 16 years 
• Patients who do not have capacity to consent for themselves 
• Weight loss surgery performed at a site outside Scotland 
• Patients who live outside Scotland 
• Patients who do not have strong enough English language skills to understand the 
patient information leaflet without assistance will be excluded from Part 2 of the study, 
the patient questionnaires. If they require a translator to understand the information 
they may be able to participate in Part 1 of the study which requires no further 
interaction from the patient. This decision will be made by the clinical teams caring for 
patients. 
 
3.6 Identification of participants and consent 
 
Patients will be prospectively identified by clinical teams as they are referred for surgery. 
Patients will be recruited from both NHS and private bariatric surgical practice in Scotland. 
They will either be recruited by a member of the surgical team prior to undergoing a 
bariatric surgical procedure, including any significant pre-operative weight loss (such as a 
very low energy diet for liver shrinkage or use of an intra-gastric balloon) which is considered 
part of the surgical pathway, or the surgical team will ask the patient’s permission to pass 
over their name and contact details to the SCOTS research team who will then contact the 
patient directly to give further information and obtain fully informed consent.  
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Depending on local patient pathways patient information sheets will be provided to patients 
at a clinic visits or group session. This will be provided at least 24 hours before the patient 
will be asked to consent. In the case of those patients who are to be recruited by the 
research team (identified by surgical team), a patient information sheet will be provided 
when the permission is sought to hand over contact details to the research team. Patients 
who meet the eligibility criteria will be identified by their local clinical care teams. All 
patients undergoing bariatric surgery will be recorded on the screening log at their next 
appointment. This will allow patients to consider their participation and ask any additional 
questions they may have about the study face to face. An independent contact is provided 
on the patient information leaflet who patients can contact to discuss participation in 
research studies.  
They will be asked to give fully informed consent for clinical data linkage (Part 1) and to be 
contacted by Glasgow University by post, email or phone about to completing the Patient 
questionnaires (Part 2) and for permission to contact them about future studies (Part 3). 
Patients who require a translator will only be asked to participate in Part 1. Only patients 
who agree to Part 1 will be eligible for Part 2 or Part 3.  
 
3.7 Withdrawal of subjects 
 
Participants have the right to withdraw from the study at any point for any reason.  The 
SCOTS web site and patient information sheets will provide contact details for patients if 
they wish to withdraw from the study. If patients have asked to complete the forms by 
paper, contact details will be included within each paper questionnaire. The SCOTS team will 
provide patients with a form to complete, if they are contacted with a request to withdraw 
from the study.  
 If the SCOTS team are contacted by a patient who no longer wishes to participate in the 
study, they will be contact by the SCOTS team at University of Glasgow and asked to specify 
which following options they would like to apply to their data:   
A. (For those within Part 1) I no longer wish to continue the study but I am content to 
allow my existing data to remain within the study for analysis. 
B. (For those consented to Part 1 and 2). I am content for my records to be linked but I 
no longer wish to complete the patient questionnaires.  
C. (For those consented to Part 1, 2 and 3). I am content for my records to be linked 
but I no longer wish to complete the patient questionnaires or be contacted regarding future 
studies.  
D. For any patient I would like to completely remove my all data from the study and 
wish not to be contacted again by the study.  
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When a request is received from a patient to withdraw from the SCOTS study, a 
standardised form will be sent to the patient by their preferred communication route. The 
form will be completed by the patient including the patients name date of birth and address, 
and the on receipt data manager will flag the patient as having withdrawn from the study. 
The patient will be asked if they would like to be informed of the findings of the study even 
though they will no longer be participating in the study. 
4 STUDY PROCEDURES 
The study design involves local clinical teams identifying and potentially recruiting 
participants (some participants will be recruited by the SCOTS research team after 
identification by the local clinical team). Patients who consent to participate will have 
recruitment data collected by their clinical care teams or the SCOTS research team. 
Following their operation patients will have their weight loss surgery details entered into the 
database. The clinical teams then use the system to include follow up weights and re-
operations. For the remainder of the study, patients who have consented to part 2 of the 
study will be asked to complete questionnaires and their health outcomes will be recorded 
by record linkage to routine data sets. A detailed breakdown of patient contacts with the 
study is described in Table 4-1 below.  
TABLE 4-1: SCOTS PATIENT VISIT SCHEDULE: DESCRIBES EACH INTERATION WITH PATIENTS IF THEY CONSENT TO PART 1 AND 
2 OF THE STUDY.  
Patie
nt 
cont
act 
Time Routine care SCOTS Par
t  
1 
Par
t 2 
Part 
3 
1 1 year to 6 
weeks 
before 
surgery 
Agree bariatric 
surgery 
Patients given/sent Invitation to 
participate letter and patient 
information sheet (and asked if 
they are to be contacted by 
SCOTS research team for further 
information and informed 
consent if no local recruitment) 
1 1  
2 1 year to 6 
weeks 
before 
surgery 
Patient pre-
surgical clinic visit, 
dietician, 
psychologist if 
local recruitment; 
phone call from 
SCOTS research 
team member if 
research team 
recruitment 
Patients asked if they are willing 
to consent to participate in 
SCOTS, Patient signs consent 
forms, clinical team and patient 
complete contact details and 
baseline height and weight. 
1 1  
3 At least one 
month 
before 
surgery 
 Patient contacted by SCOTS 
team to complete pre-operative 
questionnaire 
1 1  
4 Date of 
surgery 
Patient has weight 
loss operation 
Clinical team enters details of 
weight loss operation to SCOTS 
portal 
1 1  
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5 Patient 
admitted to 
hospital  
Identified by 
record linkage 
If patient hospital admission is 
possibly related to bariatric 
surgery, patient will be 
contacted by SCOTS Team. 
1 1  
7 At routine 
follow up 
visits 
Patients attend 
routine clinical 
visits 
Clinical teams enter weight and 
re-operation details 
 1  
8 Two year 
post surgery 
Patients have 
routine annual 
blood test and 
results are made 
available via SCI-
store. 
Patients complete two year post 
surgical questionnaire 
 1  
9 Three years 
post surgery 
Patients have 
routine annual 
blood test and 
results are made 
available via SCI-
store. 
 
Patients complete three year 
post surgical questionnaire 
 1  
10 Any point 
after 
recruitment 
 Possibly contacted to participate 
in future studies 
  1 
11 Three years 
onward 
Patient continues 
to have routine 
annual blood test 
every year 
Patient contacted to thank them 
for completing the PROMS. 
Record linkage continues. 
Patients will be informed about 
future SCOTS publications.  
 1  
Total    5 9 1 
 
 
Figure 4-1 shows what happens at each point within the study. This includes background 
record linkage and patient contacts.  
FIGURE 4-1: BASELINE – PRIOR TO OPERATIVE WEIGHT LOSS (INCLUDING PRE LIVER-PREP DIET OR BALLOON PHASE) 
Surgical/Research team enters details – CHI, BMI, date/type surgery (including 
pre-op weight loss phase)
Initial bloods taken FBC, Ca, Mg, Phos, Ferritin, B12, Folate, Vit D, albumin, 
HbA1c, CRP
GP automatically sent letter explaining study
Patient given questionnaire – including QoL, 
psychological outcomes, current meds (choice to 
complete online or paper and return)
Reminder by preferred 
mode of contact
Data-entry staff enter details from paper questionnaires 
Blood results 
collected via 
record linkage to 
SCI Store
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FIGURE 4-2: 2 AND 3 YEARS POST DEFINITIVE SURGERY  
 
 
  
Data entry staff enter details 
from paper questionnaires 
Reminder to patient 
by preferred  mode of 
communication 
Patient attends routine blood tests at pre-
arranged location for phlebotomy FBC, 
Ca, Mg, Phos, Ferritin, B12, folate, vit D, 
albumin, HbA1c, CRP and weight 
Questionnaire covers QoL, 
current meds, complications, 
psychological outcomes, plastics 
- complete online or paper 
Blood results and weight 
automatically download from Sci-
store 
Summary results sent to 
surgical team as standard 
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FIGURE 4-3: PART 3 IF NEW BARIATRIC SURGERY STUDY BEGINS 
New study on bariatric surgery 
receives ethical approvals 
SCOTS database searched for patients 
who consented to Part 3 and eligibility 
criteria checked 
Patients sent invitation letter to ask them if they 
would be interested in participating in new study
Patient considers 
participation
No further 
regarding this 
study
Decides no
New study 
protocol followed
Decides yes
 
4.1 Duration of participation  
 
Part 1: if funding is available, record linkage, follow up of patients will continue throughout 
their life. The end of a patient’s life will be shown by linkage to the GRO data set. This will be 
used to flag deceased patients. 
Part 2: patient reported outcome measures (PROMS) questionnaires will be collected for a 
maximum of 3 years. Collection of PROMS will stop after December 2020.  
Part 3: Patient contact details will be kept by the study team until the end of the patient’s 
life. The end of a patient’s life will be shown by linkage to the GRO data set. This will be used 
to flag deceased patients and they will be removed from the database in Part 3 to ensure 
patients families are not contacted after their death. Patient will only be contacted for 
future studies if record linkage is available to show that they are still living. 
Patients will be able to withdraw from the study at any point. Data collected will be retained 
unless explicitly requested to be removed from the study by the patient. 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046441:e046441. 11 2021;BMJ Open, et al. Mackenzie RM
Glasgow Clinical Trials Unit 
Surgical Obesity Treatment Study 
2017_11_22 SCOTS Protocol v1.6  Page 37 of 61 
4.2 Study schedule 
 
This section provides a brief overview of the procedures for investigators at each point 
within the study. SCOTS will integrate into routine care pathways for bariatric surgery as 
much as possible. No additional clinic visits will be required. There are five points within the 
patient journey that the clinical/research team are required to undertake any tasks. These 
points are described in detail in the following sections.  
4.2.1 Start of Study - Surgical team registration 
 
Each site will be defined before the start of the study and login and passwords will be 
created for each principal investigator and their clinical teams.  
A training plan will be developed for clinical teams. Clinical teams will be provided with an 
overview of the study provided with a training package which will be developed 
electronically, to be completed at their convenience, electronic guidance will be integrated 
into the data collection tool to assist them. A user manual will be created which will explain 
the data which is required for each field and define each data field. 
An electronic form will be used to collect surgeon specific data the first time they log onto 
the bariatric data collections system. This form will be developed by the study Data Centre at 
the Robertson Centre for Biostatistics, University of Glasgow and access to the form will be 
restricted, with only authorised site-specific personnel able to make entries or amendments 
to their data. A manual will be developed to assist investigators with use of the electronic 
data collection system.  It is the investigator's responsibility to ensure completion and to 
review and approve all data captured. Surgeons will be asked to outline which locations they 
work in, which procedures they use, and the details of these procedures.  They will also be 
asked information on their surgical experience including date when they qualified, number 
of procedures the previously year, total number of procedures undertaken in the last five 
years. 
The aim of this task is to ensure that surgeons’ data is entered at the start of the study and 
patient records can be pre-populated to ensure that data can be collected as efficiently as 
possible.  
Checklist:  
Surgeon registers on SCOTS system   
Surgeon enters names and email addresses of clinical team who will be part of 
SCOTS investigators team  
 
Investigators have the opportunity to view SCOTS training materials  
SCOTS resource pack is available at the site  
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4.2.2 Visit 1 Routine care invitation visit 
 
Patient pathways vary throughout Scotland, invitation and introduction should take place at 
either an individual’s clinic visit or at a group session discussing weight loss surgery. The aim 
of this visit is to ensure that patients who are planning weight loss surgery are aware of the 
SCOTS study, why it is being undertaken and what would be required from them.  
4.2.2.1 Invitation visit protocol (in sites with local team recruitment) 
 
1. Patient attends routine clinic to discuss bariatric surgery with clinical team. 
2. Patient provided with an overview of SCOTS 
3. Patient provided with opportunity to ask initial questions 
4. Patient provided with invitation to participate in SCOTS and patient information 
leaflet (pre-prepared pack). 
 
Checklist:  
Patients provided with overview of SCOTS   
Patient provided with SCOTS information pack  
4.2.2.2 Invitation visit protocol (in sites with SCOTS research team recruitment) 
 
5. Patient attends routine clinic to discuss bariatric surgery with clinical team. 
6. Patient provided with a summary overview of SCOTS 
7. Patient provided with invitation to participate in SCOTS and patient information 
leaflet (pre-prepared pack). 
8. Patient asked permission for surgical team to pass on contact details to SCOTS 
research team  
9. Participant Identification form completed and returned to research team 
 
Checklist:  
Patients provided with a summary overview of SCOTS   
Patient provided with SCOTS information pack  
Permission sought and Participant Identification Form completed and returned  
 
 
4.2.3 Visit 2 Recruitment visit 
At the next follow up clinic appointment patients will be asked if they wish to take part in 
SCOTS. Patients must have been given more than 24 hours to consider their participation.  
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For patient’s in sites where recruitment is carried out by the SCOTS research team the 
following will occur after the research team receive the participant information form from 
the local site: 
1. SCOTS research team contact patient via telephone 
2. Patient provided with an overview of SCOTS 
3. Patient provided with opportunity to ask initial questions 
Details of all patients who plan to have bariatric surgery will be recorded on a screening log. 
These logs will recorded on paper. Every patient who plans bariatric surgery will be logged 
anonymously with details of the individual’s age category on date of invitation, gender, 
calendar quarter surgery planned, if they meet the SCOTS eligibility criteria, if they consent 
and type of surgery planned (for participants identified via local sites but recruited by the 
SCOTS team only those giving permission for their details to be forwarded to local teams will 
have a screening log completed as the research team shall do this). The purpose of this log is 
to demonstrate if the SCOTS data set is representative of all patients who are having 
bariatric surgery in Scotland. It will also provide a record of number of patients who consent. 
A copy of the screening logs will be sent to the Robertson Centre on an annual basis. 
This is an anonymised screening record and patients who do not wish to participate will have 
no further information collected. 
4.2.3.1 Informed consent protocol (in sites with local team recruitment) 
 
1. Ask the patient if they have any questions relating to the study documentation. 
Ensure that the patient fully comprehends the information given. 
2. Explain that participation is voluntary and should they decide to proceed with 
participation in the study, they are free to withdraw at any time without giving an 
explanation.  
3. If a patient chooses to decline, thank them for their time and allow them to leave. 
4. If they are unsure, allow further time to consider and arrange a convenient date to 
meet again reiterating that their participation is voluntary. Offer the option to speak 
to another member of the study team or an independent advisor. 
5. All the check boxes within the consent form must be initialled by the patient to 
confirm they understand each part of the study. Ask the patient to initial each part 
of the consent form and sign the bottom section adding their name in block capitals. 
6. The person obtaining informed consent signs and dates the consent forms adding 
their name in block capitals. 
7. If a witness is required they can also sign and date the consent form (this may be in 
the case where an interpreter is required).  
8. One copy of the form should be provided to the patient, one filed in the patient’s 
notes and one copy stored in the site folder, and a copy sent to the Robertson 
Centre for the study files.  A copy of the version of the patient information leaflet 
which was given to the patient should be filed within the site study file. 
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9. If the patient consents to the study the patient recruitment form should be 
completed in the presence of the patient. Record patient name and CHI number (for 
NHS patients), sex, height and weight. 
10. Patients should be asked to complete the contact details part of the form including 
their e-mail and mobile phone contact details and ensure that they identify their 
preferred route of communication.  
11. The Patient recruitment form will be send to the Robertson Centre and a copy filed 
within the site study file; When they are sent to the Robertson Centre a form will be 
faxed to show what documentation has been sent in the post, this will be recorded 
in a postage log. 
12. Paper copies of the screening log are returned to the Robertson Centre annually, in 
self addressed envelopes provided by the SCOTs project team. These will also be 
recorded in a postage log.  
Checklist:  
Check patient name and date of birth correct on patient recruitment form  
Consent from signed and dated at each point  
Patient retains copy of consent form  
Copy of consent form filed in notes  
Copy of consent form in study file  
Copy of consent form in study file sent to Robertson Centre  
Copy of patient recruitment form sent to Robertson Centre  
Copy of patient recruitment form filed in study file  
Consent form and patient recruitment form entered on postage log  
4.2.3.2 Informed consent protocol  (in sites with SCOTS research team 
recruitment) 
 
1. When the Participant Identification Form is received from the surgical team start to 
complete the SCOTS Recruitment Log and contact the patient via telephone. 
2. Ask the patient if they have any questions relating to the study documentation. 
Ensure that the patient fully comprehends the information given. 
3. Explain that participation is voluntary and should they decide to proceed with 
participation in the study, they are free to withdraw at any time without giving an 
explanation.  
4. Complete the screening log (do not add participant ID as form is to be anonymous) 
5. If a patient chooses to decline, thank them for their time and allow them to leave. 
6. If they are unsure, allow further time to consider and arrange a convenient date to 
phone again reiterating that their participation is voluntary. Offer the option to 
speak to another member of the study team or an independent advisor. 
7. All the check boxes within the consent form must be initialled by the patient to 
confirm they understand each part of the study. Ask the patient to initial each part 
of the consent form and sign the bottom section adding their name in block capitals. 
8. For participants should then be asked post the completed consent form back to the 
research team in the stamped addressed envelope provided. 
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 If the research team does not receive the completed consent form from the patient within 
two weeks and cannot reach the patient by telephone, a follow up letter should then be 
sent. 
9. On receipt of the signed form, the person that obtained informed consent signs and 
dates the consent forms adding their name in block capitals. 
10. If a witness is required they can also sign and date the consent form (this may be in 
the case where an interpreter is required).  
11. One copy of the form should be provided to the patient (posted back in case of 
SCOTS team recruitment), one filed in the patient’s notes and one copy stored in the 
site folder, and a copy sent to the Robertson Centre for the study files.  A copy of the 
version of the patient information leaflet which was given to the patient should be 
filed within the site study file. 
12. If the patient consents to the study the patient recruitment form should be 
completed with the patient via the telephone. Record patient name and CHI number 
(for NHS patients), sex, height and weight. 
13. Patients should be asked for their contact details including their e-mail and mobile 
phone contact details and ensure that they identify their preferred route of 
communication.  
14. The Patient recruitment form will be send to the Robertson Centre and a copy filed 
within the site study file; When they are sent to the Robertson Centre a form will be 
faxed to show what documentation has been sent in the post, this will be recorded 
in a postage log. 
15. The Letter to Inform Surgeon of Participation should be completed and sent to the 
surgeon along with the relevant operation details recording form. 
16. Paper copies of the screening log are returned to the Robertson Centre annually, in 
self addressed envelopes provided by the SCOTS project team. These will also be 
recorded in a postage log.  
Checklist:  
Check patient name and date of birth correct on patient recruitment form  
Consent from signed and dated at each point  
Patient sent copy of signed consent form  
Copy of consent form filed in notes  
Copy of consent form in study file  
Copy of consent form in study file sent to Robertson Centre  
Copy of patient recruitment form sent to Robertson Centre  
Copy of patient recruitment form filed in study file  
Consent form and patient recruitment form entered on postage log  
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4.2.4 SCOTS study team contact patient 
 
If the patient has consented to Part 2 of the study, the patient will be contacted by staff 
from the Robertson Centre by their preferred route of communication to invite them to 
complete a patient reported outcomes questionnaire. They will be provided with a 
username and initial password which will need to be changed the first time they login to 
their account. The preadmission questionnaires will be available for the patient to complete. 
Patients will be able to complete the questionnaire in one or more sittings. If the patients 
have not logged into the system within two weeks of receiving their information they will be 
sent a reminder message by their preferred mode of contact. Given the smaller numbers 
recruited, the patients are now being offered a voucher based incentive to ensure a good 
return of the two and three year questionnaires.  They will be offered an incentive of £30 for 
completing both the year 2 and 3 questionnaires, and £10 for the year 3 weight follow-up 
questionnaire (for those no longer in clinical follow-up/not completing PROMS).   
Patients will be contacted two and three years after their weight loss operation. Patients will 
be contacted as part of the study closure phase to thank them for their participation in the 
study and inform them that they are no longer required to complete the questionnaires.  
4.2.5 Visit 3 Weight loss operation 
 
After the patient has their weight loss operation, the clinical teams will enter data onto the 
SCOTS data collection tool. This will involve the team member who has been delegated to 
record surgical information on the system. They will log in and be asked for the location of 
the surgery, which surgeon operated on the patient and their usual operation details will be 
pre-populated. If the operation is in any way different from the surgeon’s usual technique, 
an edit function will allow the exact details of the operation to be recorded.  
If the operation is a re-operation on an existing SCOTS consented patient, the SCOTS 
database will be searched to allow the patient’s re-operation to be recorded. 
 
4.2.6 Visit 4 -Post operative follow up 
 
When patients attend follow up visits to see their surgeon, clinical teams will record the 
patient’s weight and any complications experienced by the patient. If the patient has a 
gastric band, clinical teams will be able to record band adjustments in the data collection 
system. Essential fields for the follow-up visits are date of appointment and weight. Within 
the SCOTS portal it is possible for clinical teams to produce individual reports for patients on 
their weight loss for inclusion in their medical records, in the letters to GPs or for the 
patients themselves.  
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4.2.7 Visit 5 - Re-operation (If applicable) 
 
If a patient requires a re-operation, surgeons will be able to record details of the latest 
procedure and the reasons for the re-operation. This can happen at any time throughout the 
study. Details of how the surgeons will record re-operations will be included within the user 
manual.  
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5 STATISTICS AND DATA ANALYSIS 
 
5.1 Statistical Analysis Plan 
 
The study will have separate detailed Statistical Analysis Plans to cover each analyses 
required for reporting to study committees, for publications and for the final report to the 
study funder, which will be authored by the study statistician and agreed by the Study 
Steering Committee before analysis takes place. 
An important goal within the funded period is to build various predictive models to use 
accumulating information to predict good and bad outcomes, so that clinicians can identify 
treatment opportunities and make better informed intervention management decisions. 
Generically, these prediction models will relate potentially predictive information – both on 
entry into the SCOTS database on and around diagnosis, and from subsequent visits and at 
surgical and other treatment interventions – to outcomes of interest. The mainstay will be 
Cox proportional hazards time-to-event models, incorporating demographic, clinical, 
laboratory and life event data (e.g. hospitalisations, strokes, cancers, non-weight loss 
surgery, and so on) as both fixed and time varying covariates. The influence of missing data 
on the robustness of predictions in these models will be assessed. Importantly, a hierarchy 
of models will be built, with ease of use for the clinician in mind, from very simple models 
built from easy to obtain information, through to more complex models with very many and 
possibly some difficult and/or expensive to measure covariates.    
5.2 Software for statistical analysis  
 
The statistical software to be used for each analysis will be specified in the relevant 
Statistical Analysis Plan  
5.3 Sample size 
 
At the time of grant proposal writing, 230 operations were funded in NHS Scotland each year 
(of which approximately 60 are bypass). Bariatric surgeons performed an additional 270 
private procedures per year and they were willing to commit to entering data 
(approximately 80 bypass). Therefore 500 procedures per year were expected to be entered 
into the database with a belief that as numbers of people with severe obesity (BMI >40) are 
rising rapidly, this number will increase despite financial constraints.  
Previous recommendations from the NHS Scotland national planning forum 
(15)recommended that each health board should aim to provide 9 operations/100,000 
population. Scotland's estimated population on the 30th June 2011 was 5,254,800 (16) 
(http://www.gro-scotland.gov.uk/files2/stats/population-estimates/mid-
2011/j22829703.htm). This would mean around 470 operations per year within the NHS 
alone. This figure was expected to be reached over a number of years. Within private 
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healthcare bariatric surgery was estimated to be around 270 per year in Scotland (reported 
by personal communications from bariatric surgeons).  
Given the potential for a surgical learning curve (17), new surgeon’s data will be recorded 
but not analysed for the primary outcome until they have performed 50 operations. 
Collection of this early data will provide important information on the effects of the learning 
curve on patient outcomes. 
From previous studies (3;4) we expected a 10-year mortality of around 5% (100 deaths). This 
sample size would allow the mortality rate to be estimated with 95% confidence to within 
+/- 1% (i.e. for a 5% 10-year death rate, the 95% confidence interval will be between 4% and 
6%). We planned to compare this mortality rate with an age-sex matched healthy population 
from the Registrar General of Scotland’s life tables (assumed known with no sampling error). 
100 deaths was sufficient to allow us to build a predictive model for death post surgery 
(conventionally one requires around 10 events per prognostic covariate considered).  An 
initial sample size of 2000 was proposed as it would easily provide adequate power for the 
original outcomes under investigation.  
However, there have been a number of unforeseen recruitment issues that have impacted 
on the numbers stated above.  In order to explore whether the current sample is likely to 
show meaningful results, the available statistical power for detecting 3 year difference in 
HbA1c and quality of life (physical and mental components) was calculated using the 
numbers of participants available as of 29th of July 2016.  The majority of data to inform 
sample size were taken from papers where bariatric procedure was laparoscopic adjustable 
gastric banding (LAGB) as this is recognised as the least effective of the bariatric procedures 
so will give a conservative estimate of measure of effect.  This shows that there is >99% 
power to show differences in these outcomes at three years with the current sample size. 
In order to explore the likely event rate for cardiovascular events and deaths, we performed 
health record linkage for currently recruited participants, linking with inpatient care and 
death records.  Follow-up is from the date of surgery, so for those patients that went on to 
have surery details entered (n=180), there are 272 separate admissions.  Of those 272, there 
are 72 ‘emergency’ admission, and 4 of these, in 3 patients, are ‘circulatory disease’ using 
the main condition only.  The codes included for these hospital admissions are; 
· Angina pectoris (x1)  
· Acute MI (x1)  
· Pulmonary embolism without mention of acute cor pulmonale (x1)  
· Orthostatic hypotension (x1)  
 
Using date of operation as the starting point, we have a total (crude) follow-up time of 
203.52 years (the mean is 1.13 years and the median is 1.04 years). As the number of 
cardiovascular events is so low, it is impossible to extrapolate this to a future event rate at 
this time. It should be noted that the participants have been cleared as healthy for elective 
surgery meaning that it is unlikely that there would be many cardiovascular events in early 
follow-up. 
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Following discussions with the NIHR it was agreed that recruitment will stop at 
approximately 400 patients and these numbers will be sufficient to answer the majority of 
objectives initially set. 
5.4 Management and delivery 
 
The Robertson Centre for Biostatistics, part of the Glasgow Clinical Trials Unit, a fully 
registered UK CRN Clinical Trials Unit, will manage and analyse trial data. 
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6 STUDY CLOSURE 
 
Part 1 Record linkage: under the current funding record linkage will continue until December 
2020. If additional funding is available Part 1 record linkage will continue until the end of the 
patient’s life. The end of a patient’s life will be shown by linkage to the GRO data set. This 
will be used to flag deceased patient and they will be removed from the database in Part 3 
to ensure patients families are not contacted after their death.  
Part 2 Patient reported Questionnaires: The study will end when the steering committee 
agrees that one or more of the following situations applies: 
• Observation has been undertaken until December 2020 
• Sufficient patients have completed the 3 year post surgery questionnaire 
Patients will be contacted to thank them for their participation in the patient reported 
outcomes part of the study.  
Part 3 Bariatric Surgery Research Studies. Patients contact details will be maintained until 
the end of the patient’s life.  
7 Data Handling 
Data for the SCOTS study will be collected from a number of sources. These are summarised 
in Table 3-1. A detailed data management plan will be developed by the Robertson Centre 
team, which will include verification of paper data entry and validation checks. A separate 
protocol will be developed for each data linkage.  
7.1.1 Surgeon registration data 
An electronic data collection form will be developed by the study Data Centre at the 
Robertson Centre for Biostatistics, University of Glasgow. These data will include the 
surgeons’ usual procedures and registration of the clinical teams. These data will be used to 
complete the operation details for each patient. It will be the investigators responsibility to 
ensure that these data are entered correctly and are kept up to date. 
7.1.2 Patient recruitment data 
A paper case report form (CRF) will be used to collect patient contact details and height and 
weight at time of recruitment will be completed by the clinical teams when the patient has 
consented to participate in SCOTS. Patients will be asked to specify their preferred form of 
communication throughout the study. They will be told that they may be contacted via 
another route if they do not respond. This CRF will be developed by the study Data Centre at 
the Robertson Centre for Biostatistics, University of Glasgow. Competed forms will be 
checked by the clinical teams and sent to the Robertson Centre for initial data entry. These 
forms will be sent along with signed consent forms.  It is the investigator's responsibility to 
ensure completion and to review and approve all data captured in the CRF. A standard 
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operating procedure will be used by the Roberson Centre to ensure that information is 
entered into the SCOTS database in an accurate and timely manner.  
7.1.3 Surgical data collection 
An electronic case report form (e-CRF) will be used to collect data on weight loss surgery 
procedures.  On or shortly after the patient undergoes weight loss surgery a member of the 
clinical team will record specific information on the patient’s weight loss operation. Each 
surgeon will have been asked to register the locations they operate in, which procedures 
they perform and details of their usual specifications. This will then populate the fields for a 
particular type of surgery and clinical teams will be asked to confirm that the usual 
techniques have been applied for each procedure. Access to the e-CRF will be restricted, 
with only authorised site-specific personnel able to make entries or amendments to their 
patients’ data. It is the investigator's responsibility to ensure completion and to review and 
approve all data captured in the e-CRF, however, a member from the SCOTS study team, 
with the appropriate NHS Research Passport permissions, will visit the site staff at least once 
per year to ensure surgical and follow-up data are complete.  Data will be validated at the 
point of entry into the e-CRF and at regular intervals during the study.  Data discrepancies 
will be flagged to the study site and any data changes will be recorded in order to maintain a 
complete audit trail (reason for change, date change made, who made change).   
7.1.4 Patient Reported Outcomes 
An electronic case report form (e-CRF) or a paper case report form (depending on patient 
preference) will be used to collect patient reported study data.  The e-CRF and CRF will be 
developed by the study data centre at the Robertson Centre for Biostatistics, University of 
Glasgow and access to the e-CRF will be restricted, with only authorised site-specific 
personnel able to make entries or amendments to their patients’ data. All data handling 
procedures will be detailed in a study specific Data Management Plan. 
7.1.5 Routine clinical information 
A number of features have been built into the SCOTS system which will be available for 
surgeons to use during routine follow up visits. Each time a patient attends, their weight will 
be recorded. Notes can be included and exported for inclusion within patient notes, 
provided for patients or within letters to GPs.  
7.1.6 Re-operation 
An electronic case report form (e-CRF) will be used to collect data on re-operations.  On or 
shortly after the patient undergoes weight loss surgery a member of the clinical team will 
record specific information on the patients repeat weight loss operation. Not only will the 
details of the operation be recorded but the reason for operation will be included within the 
e-CRF. 
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7.1.7 Record Retention 
 
To enable evaluations and/or audits from regulatory authorities, the investigator agrees to 
keep records, including the identity of all participating subjects (sufficient information to link 
records), all original signed informed consent forms, source documents, and detailed records 
of treatment disposition in accordance with ICH GCP, local regulations, or as specified in the 
Clinical Study Agreement, whichever is longer.  Data will be retained at the Robertson Centre 
once the recruitment phase of the study is complete. During recruitment a copy of the 
patient consent form and the patient registration will be retained within the site file and 
within the patient notes.  
7.1.8 Access to data 
Clinical teams will be able to access their own data. All patients who have been entered 
within the SCOTS system will be viewed by the clinical teams who entered data. Data which 
is routinely collected for the National Bariatric Surgery Registry (NBSR) can be entered within 
the system for surgeons who wish to contribute to this process. Surgeons fully anonymised 
data (no patient identifiable information) can be exported to a file which surgeons can share 
with the NBSR if they surgeons wish to contribute. The management and approvals for this 
will be responsibility of the investigating surgeon and data will not be shared by the SCOTS 
team.  
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8 SCOTS STUDY MANAGEMENT 
 
8.1 Study Sponsor 
 
NHS Greater Glasgow and Clyde Research and Development Office as study sponsors are 
responsible for the management and conduct (according to GCP). The SCOTS steering 
committee (SSC) oversee the management and conduct of the study and report to and 
advise the sponsor on the study. All minutes from both the SCOTS management group (SMG) 
and SCOTS steering committee (SSC) are copied to NHS Greater Glasgow and Clyde Research 
and Development Office 
8.2 SCOTS Study Team 
 
A study team comprising of the chief investigator, a research lead and a project manager, in 
collaboration with the data management team based at the Robertson Centre will run the 
project on a day to day basis. Issues arising from patients or investigators will be managed by 
this team and those that cannot be resolved by that team will be discussed with the chief 
Investigator and escalated to the study management group for discussion.  
8.3 SCOTS Principal investigators 
 
Each site will have an identified principal investigator who will oversee the application of this 
protocol locally. Each member of the clinical team involved in the study will be required to 
register for a login and password to access the e-CRF through the SCOTS data collection 
portal. Any member of the local clinical teams who has registered username and password 
and entered data to the SCOTS data collection portal will be a member of the SCOTS 
Investigators Group. The investigators will be required to enter some initial registration data 
to link themselves with the surgeons they work with. Planned publications outlined in Table 
15-1 will be written on behalf of the SCOTS Investigators Group.  
8.4 Routine management of study: SCOTS Management Group (SMG) 
 
The trial will be coordinated from the University of Glasgow by the SCOTS management 
group (SMG). The SMG will consist of the principal investigator, other co-applicants, project 
manager and representatives from the Clinical Trials Unit. The role of the group is to monitor 
all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to 
and take appropriate action to safeguard participants and the quality of the trial itself. It will 
be responsible for the day to day running of the trial and budget. It will meet at least 6 
monthly, with more meetings initially and as required, and provide information to the 
steering committee as to the progress of the study.  
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8.5 SCOTS Steering Committee (SSC) 
 
SCOTS Steering Committee (SSC) will be established to provide overall supervision of the 
study and ensure adherence to GCP. It will have an independent chair, a patient 
representative, and at least two other independent academics along with the principal 
investigator. Observers from the HTA programme will be invited to SSC meetings, and all SSC 
papers will be supplied to the HTA programme. The SSC will meet at the start of the study, 
and annually thereafter. 
The role of the SSC is to provide overall supervision of the trial and ensure that it is being 
conducted in accordance with the principles of GCP and the relevant regulations. The SSC 
will: 
• agree the trial protocol and any protocol amendments 
• provide advice to the investigators on all aspects of the trial 
• include members who are independent of the investigators, in particular an 
independent chairperson. 
Decisions about continuation or termination of the trial or substantial amendments to the 
protocol are usually the responsibility of the SSC who advise the sponsor. 
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9 STUDY MONITORING/AUDITING 
 
This study is a cohort study. It will therefore be audited on random sampling basis by GG&C 
auditors on behalf of the GG&C sponsor who audit 10% of sponsored studies per annum.  
10 PROTOCOL AMENDMENTS 
 
Any change in the study protocol will require an amendment.  Any proposed protocol 
amendments will be initiated by the CI following discussion with the SSC and any required 
amendment forms will be submitted to the regulatory authority, ethics committee and 
sponsor.  The CI and the SSC will liaise with study sponsor to determine whether an 
amendment is non-substantial or substantial.  All amended versions of the protocol will be 
signed by the CI and sponsor representative.  Before the amended protocol can be 
implemented favourable opinion/approval must be sought from the original reviewing 
Research and Ethics Committee (REC) and Research and Development (R&D) office(s). 
11 ETHICAL CONSIDERATIONS 
11.1 Ethical conduct of the study 
 
The study will be carried out in accordance with the World Medical Association Declaration 
of Helsinki (1964) and its revisions (Tokyo [1975], Venice [1983], Hong Kong [1989], South 
Africa [1996] and Edinburgh [2000]). 
Favourable ethical opinion will be sought from an appropriate REC before patients are 
entered into this study. Patients will only be allowed to enter the study once they have 
provided written informed consent. 
The CI will be responsible for updating the REC of any new information related to the study. 
11.2 Informed consent 
 
Patients will be informed of the SCOTS study as they discuss weight loss surgery with their 
clinical teams. They will be provided with an information sheet on the study by a trained 
member of the clinical teams during a routine clinic visit or during a group session depending 
on the local patient pathway. The patient will be given time to consider their participation in 
the study, review the SCOTS information sheet and ask about any concerns they may have. 
Patients will then be asked to sign the SCOTS consent form.  
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12 INSURANCE AND INDEMNITY 
 
SCOTS is sponsored by NHS Greater Glasgow & Clyde and NHS indemnity is provided under 
the Clinical Negligence and Other Risks Indemnity Scheme (CNORIS). In addition, as the 
protocol authors are employees of the University of Glasgow negligent harm caused by the 
design of the trial will be covered by the Clinical Trials Insurance policy held by the University 
of Glasgow. 
Investigators working in private healthcare will recruit to this NHS funded study as part of 
their NHS role and will therefore be covered as detailed above.   
13 FUNDING 
 
Funding source: National Institute for Health Research (NIHR) Health Technology Assessment 
Programme 
Grant Award number: 10/42/02  
Original Cost: £2,124,030 
Amended Cost: £1,516,255.60 
URL of this project on the NIHR Website:  http://www.hta.ac.uk/project/2608.asp 
Start Date: January 2012  
End date: June 2021. 
Estimated date of publication in HTA journal series:  Late 2021. This date takes account of 
time for report preparation and printing based on current average times for these activities.  
International Standard Randomised Controlled Trial Number: ISRCTN 47072588  
URL of this project on the Controlled Trials Website: http://www.controlled-
trials.com/ISRCTN47072588 
14 ANNUAL REPORTS 
 
A bi-annual progress report will be submitted to NIHR (the funder), the first being submitted 
6 months from the date that all funding started (January 2012). 
Annual reports will be submitted to the ethics committee and sponsor with the first 
submitted one year after the date that all study related approvals are in place. These reports 
will follow the template on the IRAS web site. 
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15 DISSEMINATION OF FINDINGS 
 
Study results whether, negative or positive, will be disseminated. Details of the plan for 
dissemination are detailed below. Some of the outcomes described may be reported in a 
number of peer reviewed journal articles. The SCOTS Publication and Presentation SOP (18) 
describes how this will be managed throughout the study and will ensure that NIHR 
guidance for publications is adhered to.  
 
TABLE 15-1: SCOTS PUBLICATION PLANS 
 
Date Description of  publication 
1 Jan 2015 Methods paper: Outlining the methods used in the study including 
the IT based nutritional blood monitoring and the dataset being 
collected. Published – Logue et al BMJ Open 2015;5:e008106 
2 Jul 2017 Health and socio-economic burden of severe obesity in a population 
undergoing bariatric surgery.   
3 Jul 2019 The effect of the pre and post-surgery pathway and surgical 
experience on weight and complications outcomes after bariatric 
surgery.   
4 Jun 2021 Change in health and socioeconomic factors 3 years after bariatric 
surgery. 
Full HTA report within the NIHR HTA Journal Series. 
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17 Appendix E: Summary of Patient Reported Outcome 
Questions 
 
Table 17-1 shows a summary table of each set of questions which will be asked of the 
patient, when they will be asked and if they are validated or not validated.  
 
Questions are classed as not validated in the form they are being asked if they have not been 
used in a published study and are identified by either a 0 or P in the validated column.  0 
means that the set of questions are not validated P means that the questions are partially 
validated. Partially validated question sets are where a previously published question set has 
had additional questions added in order to fulfil the SCOTS objectives.  
 
TABLE 17-1: SUMMARY OF SCOTS PATIENT REPORTED OUTCOME MEASURES. 
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PROMS Total
Total 
Male
Total 
Femal Validated baseline 2 year 3 year Total
About you
Demographics – Essential 1 1 1 P 1 1 1 3
Marital Status 1 1 1 1 1 1 1 3
Ethnicity 1 1 1 1 1 0 0 1
Education 1 1 1 1 1 0 0 1
Occupation 1 1 1 P 1 1 1 3
Health History
Your Medical History 1 1 1 1 1 0 0 1
Your Weight History 1 1 1 1 1 0 0 1
Family History 1 1 1 P 1 0 0 1
Family History of Obesity 1 1 1 0 1 0 0 1
Quality of Life
SF-12 v2 –licence required 1 1 1 1 1 1 1 3
EQ5D 5L 1 1 1 1 1 1 1 3
Patient Health Questionnaire (PHQ-9) (No permissions Free) 1 1 1 1 1 1 1 3
Generalized Anxiety Disorder GAD-7 (No permissions Free) 1 1 1 1 1 1 1 3
Impact of Weight
Impact of Weight on Quality of Life (IWQOL-Lite) – Licence required 1 1 1 1 1 1 1 3
Reproductive Health – Females only 1 0 1 1 1 1 1 3
Massachusetts Male Aging Study: Single Question Assessment Males only 1 1 0 1 1 1 1 3
International Prostate Symptom Score (IPSS) Males only 1 1 0 1 1 1 1 3
Continence 1 1 1 1 1 1 1 3
Reflux Questionnaire 1 1 1 1 1 1 1 3
Lifestyle
Smoking 1 1 1 1 1 1 1 3
The Alcohol Use Disorders Identification Test: Self-Report Version 1 1 1 1 1 1 1 3
Physical Activity IPAC short form self administered 1 1 1 1 1 1 1 3
Nutrition 1 1 1 1 1 1 1 3
Personal Outlook
Life Orientation Test (REVISED) 1 1 1 1 1 1 0 2
Expectations of Surgery 1 1 1 P 1 0 0 1
Surgical Recovery
Post operative pain (1 month acute, 6 month-1 year chronic) 1 1 1 0 0 0 0 0
Surgical site infection 1 1 1 1 0 0 0 0
Skin Excess 1 1 1 0 0 0 0 0
Plastic surgery 1 1 1 P 0 0 0 0
Healthcare and Support
Outpatient care 1 1 1 1 1 1 1 3
Contacts with other health and social care professionals 1 1 1 1 1 1 1 3
Devices and specialist equipment 1 1 1 1 1 1 1 3
Benefits 1 1 1 1 1 1 1 3
   Multivitamins and Supplements use 1 1 1 1 1 1 1 3
34 33 32 26 30 23 22 75
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Medical history questions included in baseline questionnaires/patient reported outcome 
measures (PROMs). 
Why we are asking you these questions? 
It is important to know what illness patients have before their surgery so we can look at how much 
overall health has changed after their weight loss surgery. 
Medical History 
 
1. Do you have a history of any of the following? – tick all that apply 
 
  Deep vein thrombosis  (Deep vein thrombosis (DVT) is a blood clot in 
one of the deep veins in the leg.) 
  Pulmonary embolism (A pulmonary embolism is a blood clot in the 
pulmonary artery which is the blood vessel that 
transports blood from the heart to the lungs.) 
  High blood pressure  
  Diabetes  
  Angina/heart attack  
  Heart Failure 
  Stroke/mini-stroke  
  Arthritis  
  Back problems  
  Chronic Bronchitis  
  Eczema/psoriasis  
  Asthma  
  Thyroid problems  
  Migraine 
  Anxiety/depression  
  Kidney disease  
  Liver disease  
  Cancer  
  Irritable bowel syndrome  
 
  Doctor diagnosed sleep apnoea (Obstructive sleep apnoea (OSA) is a condition 
that causes interrupted breathing during sleep 
and requires a machine to keep airways open 
while you sleep. Only check this box if your 
doctor has diagnosed sleep apnoea.) 
  Other  (please specify ______________)   
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SCOTS
Produced by Robertson Centre for Biostatistics, University of Glasgow
Draft 01
Patient Questionnaire
Smoking
Smoking
Lifestyle
This section asks about your smoking, drinking, eating and exercising habits.
Why are we asking you these questions
Smoking habits may alter after weight loss surgery.
Smoking history
Current
Former
Never
1
2
3
1.
If Current,
How many per day?1a.
If former, 
Year stopped?1a.
Y Y Y Y
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SCOTS
Produced by Robertson Centre for Biostatistics, University of Glasgow
Draft 02
Patient Questionnaire
Work
Occupation
Why are we asking you these questions
The ability to work or go about usual activity is an important part of a patient's overall health and quality of life. We are
interested to see if there is a change in your occupation before and after your weight loss surgery.
Working full time (30hrs or more per week) 1 please go to section A
Working part time (less than 30hrs or more per week) 2 please go to section A
Unable to work because of illness or disability 3 please go to section B
Student 4 please go to section A
Carer for children or relative 6 please go to section B
1. Please select a category that best describes your current employment status 
Unemployed and looking for work 5 please go to section B
Section A
What is your current occupation? Since many people have more than one job at a given time, we would like
to know about the job that is your primary source of income 
1. 
Yes 1 No 2 Not applicable 3Have you had any days off sick in the last month?2. 
If Yes, how many days in total (please only include the number of days 
you were not able to work)?
a.
Are you receiving benefits?3. Yes 1 No 2
At home and not looking for paid employment 6 please go to section B
Other 6 please go to section B
Section B
Are you receiving benefits?1. Yes 1 No 2
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Social security (benefits) questions included in baseline questionnaires/patient reported outcome 
measures (PROMs).  
Why we are asking you these questions? 
Weight loss surgery can be expensive, but often the improvements in patients’ health are great. This 
is to be used in health economic analysis which balances the cost of weight loss surgery with the 
improvements in patients’ health and wellbeing and overall cost of bariatric surgery.   
Due to the personal nature of these questions, you may choose not to complete them. 
I am happy to complete these questions 
  Yes 
  No 
 
If No, please go to the next section. 
Benefits 
1. In the past three months, you may have received some benefits from the government to 
support you.  In the table below, please tick all benefits you have received in the past 3 
months. 
 
  Attendance Allowance  
  Carer’s Allowance  
  Child Tax Credit  
  Council Tax Benefit  
  Disability Living Allowance—caring  
  Disability Living Allowance—mobility  
  Employment and Support Allowance  
  Housing Benefit  
  Income Support  
  Jobseeker’s Allowance  
  Pension Credit  
  Statutory Sick Pay  
  State Pension 
  Other (please specify ______________) 
  None 
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Healthcare utilisation (devices and specialist equipment) questions included in baseline 
questionnaires/patient reported outcome measures (PROMs). 
Why we are asking you these questions? 
Some people may require specialist equipment or devices as a result of their weight and changes in 
requirements for equipment will be considered in the overall cost of weight loss surgery. 
Devices and Specialist Equipment 
1 Do you currently use any aids or 
specialist equipment?  
 
  Yes 
  No  
If No, move to next 
section 
 
1a Stair lift   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1b. Grab rail   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1c. Bariatric bed   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1d. Bariatric shower stool   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1e. Bariatric chair   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1f. Wheel chair (bariatric)   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1g. Mobility scooter   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1h. Dressing aids   Yes 
  No 
If Yes, funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
1i. Other   Yes 
  No 
If Yes, please describe any other devices or 
specialist equipment you use. 
 ______________ 
______________ 
 
Funded by: 
  provided by Social Services  
  provided by hospital  
  bought by you 
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Group 1 Group 2 Group 3 Group 4 Group 5
Total 
Number of 
Participants 
Completing 
Question 
(N missing)
< 40 
N=24
40-44 
N=64
45-49 
N=64
50-54 
N=44
55+ 
N=53
Demographics Sex: % Male 249 (0) 33.3% 23.4% 31.3% 38.6% 22.6%
SIMD: % Q1 (Most Deprived) 247 (2) 20.8% 20.3% 25.0% 30.2% 44.2%
Medical history % DVT 249 (0) 8.3% 1.6% 3.1% 4.5% 1.9%
% Hypertension 249 (0) 45.8% 32.8% 51.6% 45.5% 41.5%
% Type 2 Diabetes 249 (0) 45.8% 39.1% 60.9% 61.4% 41.5%
% CVD 249 (0) 16.7% 9.4% 6.3% 6.8% 5.7%
% Arthritis 249 (0) 16.7% 23.4% 35.9% 22.7% 39.6%
% Back Problems 249 (0) 41.7% 45.3% 50.0% 38.6% 50.9%
% Asthma 249 (0) 0.0% 25.0% 29.7% 27.3% 43.4%
% Migraine 249 (0) 20.8% 10.9% 17.2% 25.0% 28.3%
% Irritable Bowel Syndrome 249 (0) 16.7% 18.8% 20.3% 18.2% 13.2%
% Sleep Apnoea 249 (0) 16.7% 20.3% 28.1% 27.3% 35.8%
% PCOS 167 (10) 46.7% 8.3% 17.1% 20.0% 13.2%
% Gastroesophageal Reflux 240 (9) 26.1% 38.1% 52.5% 39.5% 36.0%
Incontinence % ICIQ-UI SF Score ≥6 239 (10) 26.1% 42.2% 46.7% 40.5% 54.0%
% ICIQ-UI SF Score ≥6 (females only) 168 (9) 40.0% 42.9% 50.0% 56.0% 56.4%
% ICIQ-UI SF Score ≥6 (males only) 71 (1) 0.0% 40.0% 40.0% 17.6% 45.5%
Median (LQ, UQ) ICIQ-UI SF Score 239 (10) 0.0 (0.0; 6.0) 4.0 (0.0; 9.5) 5.0 (0.0; 8.0) 3.0 (0.0; 12.0) 9.0 (3.0; 13.0)
Depression Mean (SD) PHQ-9 Score 244 (5) 7.4 (6.6) 9.5 (6.4) 9.0 (6.1) 10.9 (6.5) 10.5 (5.9)
% PHQ-9 Score ≥10 244 (5) 26.1% 46.9% 38.1% 48.8% 51.0%
Anxiety Median (LQ, UQ) GAD-7 Score 243 (6) 4.0 (1.0; 6.0) 5.0 (2.0; 10.5) 5.5 (2.0; 9.0) 4.0 (2.0; 12.0) 7.0 (3.0; 10.0)
% GAD-7 Score ≥6 243 (6) 30.4% 42.2% 50.0% 39.5% 62.7%
Smoking 
Status
% Current 240 (9) 17.4% 4.8% 4.8% 2.3% 4.0%
% Former 30.4% 45.2% 46.8% 39.5% 48.0%
% Never 52.2% 50.0% 48.4% 58.1% 48.0%
Quality of Life
SF-12 Mean (SD) SF-12 PCS 236 (13) 43.5 (11.3) 40.3 (11.0) 37.6 (10.6) 35.3 (11.6) 31.1 (10.3)
Mean (SD) SF-12 MCS 236 (13) 48.7 (7.7) 44.8 (9.1) 45.7 (11.9) 43.8 (10.8) 46.1 (10.2)
EQ-5D-5L Median (LQ, UQ) EQ-5D-5L Score 237 (12) 0.8 (0.7; 0.9) 0.7 (0.3; 0.8) 0.6 (0.4; 0.8) 0.6 (0.4; 0.7) 0.5 (0.1; 0.6)
Mean (SD) EQ-5D-5L VAS 237 (12) 64.9 (22.6) 58.8 (22.3) 56.5 (22.5) 51.7 (18.9) 47.9 (21.8)
IWQOL-Lite 
(Standardised 
Scoring)
Mean (SD) Physical Function 243 (6) 35 (24.9) 50.5 (23.3) 54.2 (24.5) 61.1 (21.6) 74.8 (20.6)
Median (LQ, UQ) Self Esteem 242 (7) 60.7 
(42.9; 85.7)
71.4 
(53.6; 89.3)
71.4 
(39.3; 92.9)
89.3 
(71.4; 96.4)
85.7 
(71.4; 96.4)
Mean (SD) Sexual Life 231 (18) 40.8 (33.4) 58.8 (30.0) 54.2 (31.2) 60.4 (34.7) 63.7 (28.8)
Mean (SD) Public Distress 243 (6) 28.9 (25.7) 48.1 (22.4) 55.9 (25.7) 70.1 (24.1) 76.1 (19.8)
Mean (SD) Work 236 (13) 31 (30.1) 38.9 (29.3) 40 (29.2) 47.5 (25.1) 55.5 (28.6)
Mean (SD) Total Score 242 (7) 40.5 (22.5) 53.7 (18.9) 55.3 (22.0) 64.1 (19.0) 71.8 (17.5)
Supplementary Table 2. Surgical Obesity Treatment Study (SCOTS) baseline data by body mass index (BMI) 
group.
BMI (kg/m
2
)
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Healthcare 
Utilisations
% Use of Any Aids or Specialist 
Equipment
232 (17) 9.1% 21.3% 27.9% 25.6% 51.0%
Social Security % Unable to Work Due to Illness or 
Disability
248 (1) 25.0% 23.4% 23.4% 23.3% 34.0%
% Disability Living Allowance - 
Caring
236 (13) 17.4% 17.7% 21.3% 17.5% 18.0%
% Disability Living Allowance - 
Mobility
236 (13) 17.4% 19.4% 23.0% 17.5% 20.0%
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PHQ-9 scores: 0-4 = 'minimal depression'; 5-9 = 'mild depression'; 10-14 = 'moderate depression'; 15-19 = 
'moderately severe depression'; 20-27 = 'severe depression' 
2
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Group 1 Group 2 Group 3 Group 4 Group 5
Total 
Number of 
Participants 
Completing 
Question 
(N missing)
< 35 
N=36
35-44 
N=63
45-49 
N=63
50-54 
N=43
55+ 
N=44
Demographics Sex: % Male 249 (0) 22.2% 22.2% 28.6% 30.2% 43.2%
SIMD: % Q1 (Most Deprived) 247 (2) 40.0% 28.6% 14.5% 39.5% 27.3%
Medical 
history
% DVT 249 (0) 2.8% 3.2% 3.2% 0.0% 6.8%
% Hypertension 249 (0) 11.1% 36.5% 52.4% 44.2% 63.6%
% Type 2 Diabetes 249 (0) 30.6% 50.8% 54.0% 44.2% 63.6%
% CVD 249 (0) 0.0% 6.3% 6.3% 9.3% 18.2%
% Arthritis 249 (0) 5.6% 15.9% 36.5% 27.9% 59.1%
% Back Problems 249 (0) 47.2% 50.8% 31.7% 39.5% 65.9%
% Asthma 249 (0) 30.6% 22.2% 31.7% 20.9% 36.4%
% Migraine 249 (0) 27.8% 17.5% 20.6% 18.6% 15.9%
% Irritable Bowel Syndrome 249 (0) 8.3% 27.0% 23.8% 4.7% 15.9%
% Sleep Apnoea 249 (0) 5.6% 20.6% 28.6% 25.6% 50.0%
% PCOS 167 (10) 26.9% 26.1% 9.3% 7.1% 12.5%
% Gastroesophageal Reflux 240 (9) 50.0% 50.0% 36.1% 28.6% 37.2%
Incontinence % ICIQ-UI Score ≥6 239 (10) 18.2% 44.3% 50.8% 50.0% 47.6%
% ICIQ-UI Score ≥6 (females only) 168 (9) 20.0% 51.1% 55.8% 62.1% 50.0%
% ICIQ-UI Score ≥6 (males only) 71 (1) 12.5% 21.4% 38.9% 23.1% 44.4%
Median (LQ, UQ) ICIQ-UI Score 239 (10) 0.0 (0.0; 4.0) 5.0 (0.0; 11.0) 6.0 (0.0; 11.0) 5.5 (3.0; 11.0) 4.5 (0.0; 11.0)
Depression Mean (SD) PHQ-9 Score 244 (5) 9.0 (6.2) 10.3 (6.3) 9.2 (5.9) 9.1 (7.0) 10.2 (6.2)
% PHQ-9 Score ≥10 244 (5) 42.9% 50.0% 37.7% 37.2% 51.2%
Anxiety Median (LQ, UQ) GAD-7 Score 243 (6) 5.0 (2.0; 10.0) 6.0 (3.0; 12.0) 5.0 (3.0; 8.0) 5.0 (1.0; 11.0) 3.0 (1.0; 8.0)
% GAD-7 Score ≥6 243 (6) 48.6% 54.8% 42.6% 47.6% 39.5%
Smoking 
Status
% Current 240 (9) 0.0% 6.5% 5.0% 0.0% 14.0%
% Former 34.4% 45.2% 41.7% 48.8% 46.5%
% Never 65.6% 48.4% 53.3% 51.2% 39.5%
Quality of Life
SF-12 Mean (SD) SF-12 PCS 236 (13) 41.2 (11.4) 38 (10.9) 36.3 (11.8) 37.7 (11.9) 32.5 (10.1)
Mean (SD) SF-12 MCS 236 (13) 44.9 (10.9) 44.5 (10.1) 46.2 (9.2) 44.7 (10.5) 46.8 (11.5)
EQ-5D-5L Median (LQ, UQ) EQ-5D-5L Score 237 (12) 0.7 (0.6; 0.8) 0.6 (0.5; 0.8) 0.6 (0.5; 0.8) 0.7 (0.2; 0.8) 0.4 (0.2; 0.7)
Mean (SD) EQ-5D-5L VAS 237 (12) 58.8 (20.7) 55.4 (21.7) 57.1 (21.7) 55.4 (25.8) 50.0 (20.4)
IWQOL-Lite 
(Standardised 
Scoring)
Mean (SD) Physical Function 243 (6) 49.5 (20.9) 54.0 (26.1) 57.2 (26.4) 57.7 (29.3) 66.0 (20.0)
Median (LQ, UQ) Self Esteem 242 (7) 85.7 
(67.9; 92.9)
85.7 
(60.7; 96.4)
75.0 
(53.6; 92.9)
71.4 
(50.0; 92.9)
58.9 
(39.3; 82.1)
Mean (SD) Sexual Life 231 (18) 54.1 (26.5) 56.7 (32.4) 53.2 (33.7) 59.0 (31.9) 65.0 (31.2)
Mean (SD) Public Distress 243 (6) 62.7 (25.8) 61.5 (26.0) 58 (26.8) 55.7 (31.7) 52.0 (25.6)
Mean (SD) Work 236 (13) 44.3 (29.2) 42.7 (28.2) 38.8 (26.0) 47.3 (34.5) 47.1 (29.7)
Mean (SD) Total Score 242 (7) 57.4 (18.8) 59.4 (21.6) 57.0 (22.7) 58.1 (26.0) 60.3 (18.2)
Age (years)
Supplementary Table 3. Surgical Obesity Treatment Study (SCOTS) baseline data by age group.
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Healthcare 
Utilisations
% Use of Any Aids or Specialist 
Equipment
232 (17) 16.1% 14.5% 24.1% 42.5% 53.7%
Social Security % Unable to Work Due to Illness or 
Disability
248 (1) 11.1% 17.5% 25.4% 28.6% 47.7%
% Disability Living Allowance - 
Caring
236 (13) 9.4% 19.4% 17.2% 14.3% 31.0%
% Disability Living Allowance - 
Mobility
236 (13) 12.5% 17.7% 17.2% 16.7% 35.7%
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Supplementary Table 4. Significant interactions with smoking as a two-level variable 
 
Outcome Model Sub-
population 
Effect OR (95% CI) p-value 
Use of aids or 
specialist 
equipment 
Adjusted 
model as 
previously 
provided 
(smoke as 3-
level) 
  Age 3.10 (1.94, 4.95) <0.0001 
  Adjusted 
model (smoke 
as 2-level) 
  Age 3.21 (2.01, 5.12) <0.0001 
  Adjusted 
model 
extended to 
include 
age*smoke 
and 
BMI*smoke 
  Age*smoke   0.044 
      BMI*smoke   0.87 
  Adjusted 
model, for the 
effect of Age 
in each of the 
smoking sub-
populations 
ANY Smoker Age 2.35 (1.27, 4.36) 0.0065 
    NEVER 
Smoker 
Age 6.49 (2.63, 
16.00) 
<0.0001 
            
PHQ-9 (assume 
included in the 
supplementary 
tables) 
Adjusted 
model as 
previously 
provided 
(smoke as 3-
level) 
  BMI 1.33 (0.96, 1.86) 0.0865 
  Adjusted 
model (smoke 
as 2-level) 
  BMI 1.31 (0.94, 1.81) 0.1093 
  Adjusted 
model 
extended to 
include 
age*smoke 
and 
BMI*smoke 
  Age*smoke   0.8800 
      BMI*smoke   0.0156 
  Adjusted 
model, for the 
effect of Age 
ANY Smoker BMI 0.88 (0.56, 1.37) 0.5679 
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in each of the 
smoking sub-
populations 
    NEVER 
Smoker 
BMI 2.28 (1.31, 3.96) 0.0037 
            
  
Unless otherwise noted, smoking status refers to a two-level variable [any smoking (current or 
former) and never smoked] as opposed to the three-level variable (current, former and never) used 
in previous analyses. 
The sub-population model of never smokers for the use of aids and specialist equipment in the 
home outcome should be interpreted with caution due to small numbers of events. 
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 1 
Supplementary Table 5. Association of age and body mass index (BMI) with self-reported comorbidities and mental health indicators. 1 
Comorbidities and Mental Health 
Indicators 
Variable BMI (Model 11) and Age (Model 22) BMI and Age (Model 33) 
Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value 
Hypertension (N = 107)  BMI 0.97 (0.72, 1.31) 0.84 0.89 (0.63, 1.24) 0.49 
Age 2.03 (1.47, 2.79) <0.0001 2.02 (1.44, 2.85) <0.0001 
Type 2 Diabetes (N = 124) BMI 0.94 (0.69, 1.26) 0.66 0.93 (0.67, 1.30) 0.68 
Age 1.41 (1.06, 1.87) 0.02 1.36 (1.00, 1.85) 0.05 
CVD (N = 20) BMI 0.61 (0.31, 1.18) 0.14 0.71 (0.36, 1.42) 0.34 
Age 2.98 (1.52, 5.85) <0.01 2.27 (1.10, 4.67) 0.03 
Arthritis (N = 73) BMI 1.45 (1.05, 2.00) 0.02 1.62 (1.09, 2.40) 0.02 
Age 3.01 (2.00, 4.54) < 0.0001 3.64 (2.26, 5.88) < 0.0001 
Back Problems (N = 115)  BMI 1.09 (0.81, 1.47) 0.57 1.12 (0.81, 1.54) 0.49 
Age 1.21 (0.91, 1.59) 0.19 1.12 (0.83, 1.51) 0.46 
Asthma (N = 70)  BMI 1.85 (1.32, 2.59) <0.001 1.81 (1.27, 2.58) <0.01 
Age 1.12 (0.82, 1.52) 0.49 1.11 (0.79, 1.57) 0.54 
Migraine (N = 49)  BMI 1.55 (1.09, 2.20) 0.02 1.63 (1.11, 2.38) 0.01 
Age 0.85 (0.60, 1.18) 0.33 0.91 (0.62, 1.33) 0.63 
Irritable Bowel Syndrome (N = 44) BMI 0.97 (0.66, 1.44) 0.90 1.00 (0.65, 1.54) 1.00 
Age 0.98 (0.69, 1.41)  0.93 1.07 (0.71, 1.60) 0.76 
Sleep Apnoea (N = 66) BMI 1.69 (1.21, 2.36) <0.01 1.88 (1.27, 2.77) <0.01 
Age 2.28 (1.55, 3.34) < 0.0001 2.05 (1.35, 3.11) <0.001 
PCOS (N = 28) BMI 0.72 (0.42, 1.23) 0.23 0.74 (0.42, 1.30) 0.29 
Age 0.56 (0.36, 0.88) 0.01 0.56 (0.35, 0.90) 0.02 
Gastroesophageal Reflux (N = 97) BMI 1.02 (0.75, 1.39) 0.88 1.06 (0.76, 1.47) 0.73 
Age 0.73 (0.55, 0.98) 0.04 0.68 (0.50, 0.93)  0.01 
Male Incontinence (ICIQ-UI score ≥ 6)  
(N = 22) 
BMI 1.58 (0.81, 3.09) 0.18 1.99 (0.92, 4.30) 0.08 
Age 2.05 (1.05, 4.01) 0.04 2.19 (1.06, 4.53) 0.03 
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 2 
Female Incontinence (ICIQ-UI score ≥ 6)  
(N = 83) 
BMI 1.45 (1.01, 2.09) 0.05 1.40 (0.94, 2.08) 0.10 
Age 1.59 (1.10, 2.28) 0.01 1.49 (1.02, 2.19)  0.04 
Depression (PHQ-9 score ≥ 10) (N = 107) BMI 1.25 (0.92, 1.70) 0.15 1.33 (0.96, 1.86) 0.09 
Age 1.04 (0.79, 1.37) 0.79 0.99 (0.73, 1.34) 0.94 
Anxiety (GAD-7 score ≥ 6) (N = 114) BMI 1.42 (1.04, 1.95) 0.03 1.47 (1.05, 2.05) 0.03 
Age 0.91 (0.69, 1.20) 0.49 0.91 (0.67, 1.24) 0.56 
 2 
1 Model 1 – Unadjusted model including only the effect of BMI (per 10 kg/m2) on comorbidity. 3 
2 Model 2 – Unadjusted model including only the effect of age (per 10 years) on comorbidity. 4 
3 Model 3 – Model including the effects of age (per 10 years) and BMI (per 10 kg/m2) on comorbidity, after adjusting additionally for sex, Scottish Index of 5 
Multiple Deprivation (SIMD) and smoking status. 6 
Regressions analyses were performed for conditions affecting 10 or more participants only. 7 
 8 
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